{
  "$schema": "folio-library-entry/v1",
  "id": "9789241549912-websupplement-eng",
  "blocks": [
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 9,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Running header\nWeb supplement \nWHO recommendations on antenatal care \nfor a positive pregnancy experience: evidence base* \n* The full guideline document and web annexes are available at: \nhttp://www.who.int/reproductivehealth/publications/maternal_perinatal_health/anc-positive-pregnancy-experience/en/\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base\nii\nEditing, design and layout: Green Ink, United Kingdom (www.greenink.co.uk)\nContents\nAcronyms and abbreviations..............................................................................",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Front matter for the Web supplement to the WHO recommendations on antenatal care for a positive pregnancy experience (evidence base), containing publication credits (editing, design, and layout by Green Ink), the complete table of contents across Sections A (Nutritional interventions A.1–A.10), B (Maternal and fetal assessment B.1–B.2), C (Preventive measures C.1–C.5), D (Interventions for common physiological symptoms D.1–D.6), E (Health systems interventions to improve antenatal care utilization and quality E.1–E.4, E.7), and Search strategies for the evidence base (1–5), plus a list of acronyms and abbreviations (ANC, CI, EB, Hb, MD, RCT, RR, UNIMMAP).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Nutritional interventions",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-000-a-nutritional-interventions.md",
      "narrative": null,
      "content": "A. Nutritional interventions",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Part A (Nutritional interventions) of the WHO antenatal care guideline evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Dietary interventions",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/sec-001-a1-dietary-interventions.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.1.1: All diet and/or physical activity/exercise interventions versus control (standard or other care)",
      "pageStart": 9,
      "pageEnd": 16,
      "target": "../sections/sec-002-eb-table-a11-all-diet-andor-physical-activityexe.md",
      "narrative": null,
      "content": "Source: Muktabhant B, Lawrie TA, Lumbiganon P, Laopaiboon M. Diet or exercise, or both, for preventing excessive weight gain in pregnancy. Cochrane Database Syst Rev. 2015;(6):CD007145.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAll diet and/\nor exercise \ninterventions\nStandard/other \ncare\nRelative \n(95% CI)\nAbsolute\nPre-eclampsia – all interventions\n15\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n170/2783 \n(6.1%)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.1.1) from the Cochrane review by Muktabhant et al. (2015) comparing all diet and/or physical activity/exercise interventions during pregnancy against standard or other care. Presents GRADE quality assessments, study counts, event rates, relative risks, absolute effects, and certainty ratings across overall and intervention-subgroup analyses for pre-eclampsia (RR 0.95, high certainty), caesarean section (RR 0.95, low certainty; diet and exercise counselling RR 0.87, high certainty), excessive gestational weight gain (RR 0.80, high certainty, with consistent reductions across diet, counselling, and supervised/unsupervised exercise subgroups), preterm birth (RR 0.91, low certainty), macrosomia (> 4000 g; RR 0.93, moderate certainty), low birth weight (< 2500 g; RR 0.88, very low certainty), induction of labour (RR 1.06, moderate certainty), shoulder dystocia (RR 1.02, moderate certainty), neonatal hypoglycaemia (RR 0.95, moderate certainty), and neonatal respiratory distress (RR 0.47, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Figure A.1.1: Additional meta-analysis: Effect of diet and/or exercise interventions versus control on gestational diabetes mellitus (GDM)",
      "pageStart": 16,
      "pageEnd": 18,
      "target": "../sections/sec-003-figure-a11-additional-meta-analysis-effect-of-di.md",
      "narrative": null,
      "content": "Figure A.1.1: \t Additional meta-analysis: Effect of diet and/or exercise interventions versus \ncontrol on gestational diabetes mellitus (GDM) (not included in the systematic \nreview by Muktabhant et al., 2015 [see EB Table A.1.1])\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base\n9\nEB Table A.1.2: Energy and protein nutrition education during pregnancy versus control (no nutritional education or normal care)\nSource: Ota E, Hori H, Mori R, Tobe-Gai R, Farrar D. Antenatal dietary education and supplementation to increase energy and protein",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Caption for Figure A.1.1 (additional meta-analysis on the effect of diet and/or exercise interventions versus control on gestational diabetes mellitus, not included in Muktabhant et al., 2015) followed by EB Table A.1.2 from Ota et al. (2015) evaluating antenatal energy and protein nutrition education versus no nutritional education or normal care. Reports GRADE evidence profiles for total gestational weight gain (MD 0.41 kg lower, very low certainty), small for gestational age (RR 0.97, low certainty), low birth weight (RR 0.04, low certainty), preterm birth (RR 0.46, very low certainty), stillbirth (RR 0.37, low certainty), and neonatal death (RR 1.28, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.1.3: Energy and protein dietary supplements versus control",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-004-eb-table-a13-energy-and-protein-dietary-suppleme.md",
      "narrative": null,
      "content": "EB Table A.1.3: Energy and protein dietary supplements versus control\nSource: Ota E, Hori H, Mori R, Tobe-Gai R, Farrar D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database Syst Rev. 2015;(6):CD000032.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nBalanced protein/energy \nsupplementation \nControl\nRelative\n(95% CI)\nAbsolute\nPre-eclampsia\n2\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n25/231",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.1.3) from Ota et al. (2015) comparing balanced energy and protein dietary supplementation during pregnancy with control. Summarizes GRADE evidence showing reductions in small-for-gestational-age neonates (7 RCTs; RR 0.79, 95% CI 0.69–0.90; 36 fewer per 1000; moderate certainty) and stillbirth (5 RCTs; RR 0.60, 95% CI 0.39–0.94; 12 fewer per 1000; moderate certainty), alongside estimates for pre-eclampsia (RR 1.48, very low certainty), preterm birth (RR 0.96, moderate certainty), and neonatal death (RR 0.68, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.1.4: High-protein supplements versus control",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-005-eb-table-a14-high-protein-supplements-versus-con.md",
      "narrative": null,
      "content": "EB Table A.1.4: High-protein supplements versus control\nSource: Ota E, Hori H, Mori R, Tobe-Gai R, Farrar D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database Syst Rev. 2015;(6):CD000032.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nHigh-protein \nsupplementation \nControl\nRelative\n(95% CI)\nAbsolute\nSmall for gestational age\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nserious\nnone\n46/249 \n(",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.1.4) from Ota et al. (2015) evaluating high-protein dietary supplementation versus control during pregnancy (1 RCT). Reports GRADE evidence demonstrating an increased risk of small-for-gestational-age neonates (RR 1.58, 95% CI 1.03–2.41; 68 more per 1000; high certainty), with uncertain effects on preterm birth (RR 1.14, moderate certainty), stillbirth (RR 0.81, low certainty), and neonatal death (RR 2.78, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Iron and folic acid supplements",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../sections/sec-006-a2-iron-and-folic-acid-supplements.md",
      "narrative": null,
      "content": "A.2. Iron and folic acid supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.2 (Iron and folic acid supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.2.1: Daily iron and folic acid supplements versus control (supplements without iron or no treatment/placebo)",
      "pageStart": 20,
      "pageEnd": 24,
      "target": "../sections/sec-007-eb-table-a21-daily-iron-and-folic-acid-supplemen.md",
      "narrative": null,
      "content": "Source: Peña-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015;(7):CD004736.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nDesign \nlimitations\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAny \nsupplements \ncontaining iron\nSame \nsupplements \nwithout iron or \nno treatment/\nplacebo (no iron \nor placebo)\nRelative\n(95% CI)\nAbsolute\nMaternal anaemia at term (Hb < 110 g/L at 37 weeks of gestation or more) \n14\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \ni",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.2.1) from Peña-Rosas et al. (2015) comparing daily oral iron and folic acid supplementation during pregnancy against supplements without iron or placebo/no treatment. Presents GRADE ratings across maternal and perinatal outcomes, showing reduced maternal anaemia at term (RR 0.30, low certainty), higher maternal haemoglobin at or near term (MD 8.88 g/L higher, low certainty), increased high haemoglobin concentrations (> 130 g/L; RR 3.07, low certainty), reduced severe postpartum anaemia (RR 0.04, low certainty), reduced puerperal infection (RR 0.68, moderate certainty), reduced diarrhoea (RR 0.55, high certainty), reduced very preterm birth (< 34 weeks; RR 0.51, high certainty), and effects on maternal death, side-effects, antepartum/postpartum haemorrhage, transfusion, constipation, nausea, heartburn, vomiting, maternal satisfaction, placental abruption, pre-eclampsia, low birth weight (RR 0.84, low certainty), preterm birth (< 37 weeks; RR 0.93, high certainty), neonatal death, and congenital anomalies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.2.2: Intermittent iron and folic acid supplements versus daily regimen with no iron",
      "pageStart": 24,
      "pageEnd": 27,
      "target": "../sections/sec-008-eb-table-a22-intermittent-iron-and-folic-acid-su.md",
      "narrative": null,
      "content": "EB Table A.2.2: Intermittent iron and folic acid supplements versus daily regimen with no iron\nSource: Peña-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015;(19):CD009997.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nDesign \nlimitations\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAny intermittent \niron regimen \n(with or without \nother vitamins \nand minerals) \nDaily regimen \n(with same \nvitamins and \nminerals but no \niron)\nRelative\n(95% CI)\nA",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.2.2) from Peña-Rosas et al. (2015) comparing intermittent oral iron and folic acid regimens during pregnancy against daily iron supplementation regimens. Provides GRADE evidence profiles showing higher maternal anaemia at or near term (RR 1.66, moderate certainty), lower risk of high haemoglobin concentrations (> 130 g/L) in the second or third trimester (RR 0.53, moderate certainty), fewer overall side-effects (RR 0.56, very low certainty) and nausea (RR 0.60, moderate certainty), no events of severe anaemia (< 70 g/L; moderate certainty), and low- to very-low-certainty estimates for maternal anaemia at term, severe postpartum anaemia, mean haemoglobin concentration, antepartum haemorrhage, placental abruption, diarrhoea, constipation, heartburn, vomiting, preterm rupture of membranes, low birth weight (RR 0.82), preterm birth (RR 1.03), very preterm birth, and neonatal death.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Calcium supplements",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-009-a3-calcium-supplements.md",
      "narrative": null,
      "content": "A.3. Calcium supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.3 (Calcium supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.3: Calcium supplements versus placebo or no treatment",
      "pageStart": 27,
      "pageEnd": 30,
      "target": "../sections/sec-010-eb-table-a3-calcium-supplements-versus-placebo-o.md",
      "narrative": null,
      "content": "Source: Buppasiri P, Lumbiganon P, Thinkhamrop J, Ngamjarus C, Laopaiboon M, Medley N. Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes. \nCochrane Database Syst Rev. 2015;(2):CD007079.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nCalcium \nsupplementation \nPlacebo or no \ntreatment \nRelative\n(95% CI)\nAbsolute\nMaternal anaemia\n1\nrandomized \ntrials\nno serious \nrisk of bias\nno serious \ninconsistency\nno serious \nindirectness\nno s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.3) from Buppasiri et al. (2015) evaluating calcium supplementation (other than for preventing or treating hypertension) versus placebo or no treatment for maternal and infant outcomes. Reports GRADE evidence showing little or no difference in maternal anaemia (RR 1.04, high certainty), caesarean section (RR 0.99, high certainty), side-effects (RR 1.02, high certainty), urinary tract infection, maternal weight gain, maternal death, gall stones, urinary stones, renal colic, impaired renal function, low birth weight (RR 0.93, moderate certainty), stillbirth (RR 0.91, moderate certainty), and perinatal mortality (RR 0.87, low certainty), while high-dose calcium supplementation reduced preterm birth (12 RCTs; RR 0.81, 95% CI 0.66–0.99; moderate certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vitamin A supplements",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../sections/sec-011-a4-vitamin-a-supplements.md",
      "narrative": null,
      "content": "A.4. Vitamin A supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.4 (Vitamin A supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.4: Vitamin A supplements alone versus placebo or no treatment",
      "pageStart": 30,
      "pageEnd": 32,
      "target": "../sections/sec-012-eb-table-a4-vitamin-a-supplements-alone-versus-p.md",
      "narrative": null,
      "content": "Source: McCauley ME, van den Broek N, Dou L, Othman M. Vitamin A supplementation during pregnancy for maternal and newborn outcomes. Cochrane Database Syst Rev. 2015;(10):CD008666.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nVitamin A alone \nControl (placebo \nor no treatment)\nRelative\n(95% CI)\nAbsolute\nMaternal anaemia\n3\nrandomized \ntrials\n no serious \nrisk of bias\nserious1\nno serious \nindirectness\nno serious \nimprecision\nnone\n2699 \n1119 \nRR 0.64 \n(0.43 to 0.94)\n-\nMODERATE\nMaternal infection\n5",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.4) from McCauley et al. (2015) comparing antenatal vitamin A supplementation alone against placebo or no treatment. Summarizes GRADE evidence indicating reductions in maternal anaemia (3 RCTs; RR 0.64, moderate certainty), maternal infection (5 RCTs; RR 0.45, low certainty), and maternal night blindness (2 RCTs; RR 0.79, low certainty), with no clear effect on perinatal mortality (RR 1.01, high certainty), neonatal mortality (RR 0.97, high certainty), stillbirth (RR 1.04, high certainty), maternal death (RR 0.88, moderate certainty), low birth weight (RR 1.02, moderate certainty), or preterm birth (RR 0.98, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Zinc supplements",
      "pageStart": 32,
      "pageEnd": 32,
      "target": "../sections/sec-013-a5-zinc-supplements.md",
      "narrative": null,
      "content": "A.5. Zinc supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.5 (Zinc supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.5: Zinc supplements versus no intervention or placebo",
      "pageStart": 32,
      "pageEnd": 34,
      "target": "../sections/sec-014-eb-table-a5-zinc-supplements-versus-no-intervent.md",
      "narrative": null,
      "content": "Source: Ota E, Mori R, Middleton P, Tobe-Gai R, Mahomed K, Miyazaki C, Bhutta ZA. Zinc supplementation for improving pregnancy and infant outcome. Cochrane Database Syst Rev. 2015;(2):CD000230.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nVitamin A alone \nControl (placebo \nor no treatment)\nRelative\n(95% CI)\nAbsolute\nAny maternal infection\n3\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nserious1\nnone\n52/585 \n(8.9%)\n50/600 \n(8.3%)\nRR 1.06 \n(0.74 to",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.5) from Ota et al. (2015) evaluating zinc supplementation versus placebo or no intervention during pregnancy. Reports GRADE evidence showing a reduction in preterm birth (16 RCTs; RR 0.86, 95% CI 0.76–0.97; 18 fewer per 1000; low certainty), with no clear difference across maternal infection (RR 1.06, moderate certainty), pregnancy hypertension or pre-eclampsia (RR 0.83, very low certainty), caesarean section (RR 0.95, very low certainty), instrumental vaginal birth (RR 1.12, very low certainty), smell or taste dysfunction side-effects, neonatal infection (RR 0.17, low certainty), small for gestational age (RR 1.02, low certainty), low birth weight (RR 0.93, low certainty), or congenital malformation (RR 0.67, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Multiple micronutrient (MMN) supplements",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../sections/sec-015-a6-multiple-micronutrient-mmn-supplements.md",
      "narrative": null,
      "content": "A.6. Multiple micronutrient (MMN) supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.6 (Multiple micronutrient (MMN) supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.6: Multiple micronutrient supplements versus iron (with or without folic acid)1",
      "pageStart": 34,
      "pageEnd": 36,
      "target": "../sections/sec-016-eb-table-a6-multiple-micronutrient-supplements-v.md",
      "narrative": null,
      "content": "Source: Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev. 2015;(11):CD004905.\nQuality assessment\nNo. of women1\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\n13–15 micronutrients\nIron (with or without \nfolic acid)\nRelative\n(95% CI)\nMaternal anaemia (third trimester Hb < 110 g/L)\n5\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n5132\n5134\nRR 0.98 \n(0.85 to 1.13)\nHIGH\nCaesarean section\n4\nr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.6) from Haider and Bhutta (2015) comparing multiple micronutrient (MMN) supplements containing 13–15 micronutrients against iron supplements (with or without folic acid) during pregnancy. Reports GRADE ratings showing a reduction in low birth weight (14 RCTs; RR 0.88, 95% CI 0.85–0.91; high certainty) and a borderline reduction in small for gestational age (13 RCTs; RR 0.98, 95% CI 0.96–1.00; moderate certainty), alongside little or no difference in maternal third-trimester anaemia (RR 0.98, high certainty), preterm birth (RR 0.95, high certainty), caesarean section (RR 1.03, moderate certainty), perinatal mortality (RR 1.00, moderate certainty), stillbirths (RR 0.97, moderate certainty), neonatal mortality (RR 0.99, moderate certainty), maternal mortality (RR 0.97, low certainty), and congenital anomalies (RR 0.99, low certainty), plus an introductory note on the additional iron-dose subgroup and UNIMMAP meta-analyses.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "i. Subgroup analyses grouping trials according to dose of iron in the control group",
      "pageStart": 36,
      "pageEnd": 47,
      "target": "../sections/sec-017-i-subgroup-analyses-grouping-trials-according-to.md",
      "narrative": null,
      "content": "1. Maternal anaemia\n2\t Folic acid is 0.4 mg in the control group for all trials unless footnoted.\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base\n29\ni. Subgroup analyses grouping trials according to dose of iron in the control group (60 mg, 30 mg or not stated) (continued) \n2. Caesarean section\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base\n30\ni. Subgroup analyses grouping trials according to dose of iron in the control group (60 mg, 30 mg or not stated) (continued) \n3. Maternal",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section headings and figure captions (pages 28–39) for the additional subgroup meta-analyses of multiple micronutrient (MMN) supplementation trials grouped by the iron dose in the control arm (60 mg, 30 mg, or not stated, with 0.4 mg folic acid unless footnoted), covering maternal anaemia (1), caesarean section (2), maternal mortality (3), small for gestational age (4 and exploratory analysis 4b restricted to 60 mg or 30 mg iron plus 0.4 mg folic acid controls), low birth weight (5), preterm birth (6), congenital anomalies (7), perinatal mortality (8), stillbirth (9), and neonatal mortality (10 and exploratory analysis 10b).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Meta-analyses of trials evaluating UNIMMAP supplements with trials grouped according to dose of iron in the control group",
      "pageStart": 47,
      "pageEnd": 56,
      "target": "../sections/sec-018-ii-meta-analyses-of-trials-evaluating-unimmap-su.md",
      "narrative": null,
      "content": "group (60 mg, 30 mg or not stated)3\n1. Maternal anaemia\n3 Folic acid is 0.4 mg in the control group for all trials unless footnoted.\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base\n40\nii. Meta-analyses of trials evaluating UNIMMAP supplements with trials grouped according to dose of iron in the control group (60 mg, 30 mg or not stated) (continued)\n2. Caesarean section\n3. Maternal mortality\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base\n41\nii. Meta-analyses of trials evaluating",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section headings and figure captions (pages 39–47) for the additional meta-analyses of trials specifically evaluating the United Nations international multiple micronutrient preparation (UNIMMAP) supplement, grouped by the control group iron dose (60 mg, 30 mg, or not stated, with 0.4 mg folic acid unless footnoted), across maternal anaemia (1), caesarean section (2), maternal mortality (3), small for gestational age (4), low birth weight (5), preterm birth (6), congenital anomalies (7), perinatal mortality (8), stillbirth (9), and neonatal mortality (10a and exploratory analysis 10b restricted to 60 mg or 30 mg iron plus 0.4 mg folic acid controls).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vitamin B6 (pyridoxine) supplements",
      "pageStart": 56,
      "pageEnd": 56,
      "target": "../sections/sec-019-a7-vitamin-b6-pyridoxine-supplements.md",
      "narrative": null,
      "content": "A.7. Vitamin B6 (pyridoxine) supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.7 (Vitamin B6 (pyridoxine) supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.7: Vitamin B6 (pyridoxine) supplements versus control",
      "pageStart": 56,
      "pageEnd": 57,
      "target": "../sections/sec-020-eb-table-a7-vitamin-b6-pyridoxine-supplements-ve.md",
      "narrative": null,
      "content": "Source: Salam RA, Zuberi NF, Bhutta ZA. Pyridoxine (vitamin B6) supplementation during pregnancy or labour for maternal and neonatal outcomes. Cochrane Database Syst Rev. 2015;(6):CD000179.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nPyridoxine (B6)\nControl\nRelative\n(95% CI)\nAbsolute\nPre-eclampsia – antenatal oral pyridoxine tablets \n2\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n21/604 \n(3.5%)\n12/593 \n(2%)\nRR 1.71 \n(0.85 to 3.45)\n14 more per 100",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.7) from Salam et al. (2015) comparing antenatal vitamin B6 (pyridoxine) supplementation against control. Reports GRADE evidence for pre-eclampsia with antenatal oral pyridoxine tablets (2 RCTs; RR 1.71, 95% CI 0.85–3.45; low certainty) and antenatal pyridoxine lozenges (1 RCT; RR 1.43, 95% CI 0.64–3.22; very low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vitamin E and C supplements",
      "pageStart": 57,
      "pageEnd": 57,
      "target": "../sections/sec-021-a8-vitamin-e-and-c-supplements.md",
      "narrative": null,
      "content": "A.8. Vitamin E and C supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.8 (Vitamin E and C supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.8a: Vitamin E and C supplementation versus placebo or no treatment",
      "pageStart": 57,
      "pageEnd": 60,
      "target": "../sections/sec-022-eb-table-a8a-vitamin-e-and-c-supplementation-ver.md",
      "narrative": null,
      "content": "Source: Rumbold A, Ota E, Hori H, Miyazaki C, Crowther CA. Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev. 2015;(9):CD004069.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAny vitamin \nE and C \nsupplementation\nControl (placebo \nor no treatment)\nRelative\n(95% CI)\nAbsolute\nPre-eclampsia \n14\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nreporting \nbias1\n968/10 423 \n(9.3%)\n997/10 455 \n(9.5%)\nRR 0.91 \n(0.79 t",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.8a) from Rumbold et al. (2015) comparing combined vitamin E and C supplementation during pregnancy against placebo or no treatment. Presents GRADE evidence showing increased risks of abdominal pain (1 RCT; RR 1.66, high certainty) and term prelabour rupture of membranes (PROM >= 37 weeks; 2 RCTs; RR 1.77, high certainty), a reduction in placental abruption (7 RCTs; RR 0.64, moderate certainty), and no clear benefit for pre-eclampsia (14 RCTs; RR 0.91, moderate certainty), eclampsia (RR 1.67, moderate certainty), caesarean section (RR 1.02, high certainty), induction of labour, maternal death, antepartum haemorrhage, overall side-effects, small for gestational age (RR 0.98, high certainty), preterm birth (RR 0.98, moderate certainty), congenital malformations, stillbirth, neonatal death, perinatal death, or preterm PROM (RR 1.27, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.8b: Vitamin C supplementation alone versus placebo or no treatment",
      "pageStart": 60,
      "pageEnd": 61,
      "target": "../sections/sec-023-eb-table-a8b-vitamin-c-supplementation-alone-ver.md",
      "narrative": null,
      "content": "EB Table A.8b: Vitamin C supplementation alone versus placebo or no treatment\nSource: Rumbold A, Ota E, Hori H, Miyazaki C, Crowther CA. Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev. 2015;(9):CD004069.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nVitamin C alone \nPlacebo or no \ntreatment\nRelative\n(95% CI)\nAbsolute\nPrelabour rupture of membranes (PROM)\n6\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n64/722 \n(8.9%",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.8b) from Rumbold et al. (2015) evaluating vitamin C supplementation alone versus placebo or no treatment during pregnancy. Reports GRADE evidence for overall prelabour rupture of membranes (6 RCTs; RR 0.63, 95% CI 0.48–0.83; moderate certainty), preterm PROM (5 RCTs; RR 0.66, 95% CI 0.48–0.91; moderate certainty), and term PROM (1 RCT; RR 0.55, 95% CI 0.32–0.94; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vitamin D supplements",
      "pageStart": 61,
      "pageEnd": 61,
      "target": "../sections/sec-024-a9-vitamin-d-supplements.md",
      "narrative": null,
      "content": "A.9. Vitamin D supplements",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.9 (Vitamin D supplements) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.9: Vitamin D supplementation alone or with calcium versus placebo or no treatment",
      "pageStart": 61,
      "pageEnd": 63,
      "target": "../sections/sec-025-eb-table-a9-vitamin-d-supplementation-alone-or-w.md",
      "narrative": null,
      "content": "Source: De-Regil LM, Palacios C, Lombardo LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2016;(1):CD008873.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nIntervention\nControl\nRelative\n(95% CI)\nAbsolute\nVitamin D supplementation alone versus placebo or no treatment\nPre-eclampsia \n2\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nvery serious2,3\nnone\n12/135 \n(8.9%)\n13/84 \n(15.5%)\nRR 0.52 \n(0.25 to 1.05)\n74 fe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.9) from De-Regil et al. (2016) evaluating antenatal vitamin D supplementation alone or combined with calcium versus placebo or no treatment. For vitamin D alone, reports GRADE evidence of low certainty for reductions in preterm birth (3 RCTs; RR 0.36, 95% CI 0.14–0.93) and low birth weight (3 RCTs; RR 0.40, 95% CI 0.24–0.67), alongside low- or very-low-certainty estimates for pre-eclampsia (RR 0.52), gestational diabetes (RR 0.43), caesarean section (RR 0.95), maternal death, stillbirth (RR 0.35), and neonatal death (RR 0.27). For vitamin D plus calcium, shows reduced pre-eclampsia (3 RCTs; RR 0.51, 95% CI 0.32–0.80; moderate certainty) but increased preterm birth (3 RCTs; RR 1.57, 95% CI 1.02–2.43; moderate certainty), with uncertain effects on gestational diabetes and neonatal death.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Restricting caffeine intake",
      "pageStart": 63,
      "pageEnd": 63,
      "target": "../sections/sec-026-a10-restricting-caffeine-intake.md",
      "narrative": null,
      "content": "A.10. Restricting caffeine intake",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Section A.10 (Restricting caffeine intake) under Nutritional interventions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.10a: Caffeinated coffee versus decaffeinated coffee",
      "pageStart": 63,
      "pageEnd": 64,
      "target": "../sections/sec-027-eb-table-a10a-caffeinated-coffee-versus-decaffei.md",
      "narrative": null,
      "content": "Source: Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes. Cochrane Database Syst Rev. 2015;(6):CD006965.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nCaffeinated \ncoffee\nDecaffeinated \ncoffee\nRelative\n(95% CI)\nAbsolute\nPreterm birth\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nserious1\nserious2\nnone\n23/552 \n(4.2%)\n31/601 \n(5.2%)\nRR 0.81 \n(0.48 to 1.37)\n10 fewer per 1000 \n(from 27 fewer to 19 more)\nMODERAT",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table A.10a) from the Cochrane review by Jahanfar and Jaafar (2015) comparing caffeinated coffee against decaffeinated coffee during pregnancy (1 RCT). Reports moderate-certainty GRADE evidence showing no clear difference in preterm birth (RR 0.81, 95% CI 0.48–1.37) or small for gestational age (RR 0.97, 95% CI 0.57–1.64), downgraded for indirectness (only coffee restricted) and wide confidence intervals.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.10b: Non-randomized evidence of effect of caffeine on low birth weight – 1",
      "pageStart": 64,
      "pageEnd": 65,
      "target": "../sections/sec-028-eb-table-a10b-non-randomized-evidence-of-effect.md",
      "narrative": null,
      "content": "EB Table A.10b: Non-randomized evidence of effect of caffeine on low birth weight – 1\nSource: Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM. Maternal caffeine intake during pregnancy is associated with risk of low birth weight: a \nsystematic review and dose-response meta-analysis. BMC Med. 2014;12:174. doi:10.1186/s12916-014-0174-6.\nQuality assessment\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nRelative \n(95% CI)\nLow birth weight – high caffeine intake vs very low or no caffeine intake\n8\nobservational \nstudies1\nn",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base tables (EB Table A.10b – 1 and 2) summarizing non-randomized observational meta-analyses on maternal caffeine intake during pregnancy and low birth weight. Part 1 (Chen et al., 2014) shows a dose-dependent increase in low birth weight risk across low (RR 1.13, moderate certainty), moderate (RR 1.38, low certainty), and high (RR 1.60, very low certainty) caffeine intake versus very low or no intake; Part 2 (Rhee et al., 2015; 12 observational studies) likewise shows higher odds of low birth weight for higher versus lower caffeine intake (OR 1.38, 95% CI 1.10–1.73; moderate certainty, upgraded for linear dose–response gradient).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table A.10c: Non-randomized evidence of effect of caffeine on pregnancy loss – 1",
      "pageStart": 65,
      "pageEnd": 67,
      "target": "../sections/sec-029-eb-table-a10c-non-randomized-evidence-of-effect.md",
      "narrative": null,
      "content": "EB Table A.10c: Non-randomized evidence of effect of caffeine on pregnancy loss – 1\nSource: Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM. Maternal caffeine intake during pregnancy and risk of pregnancy loss: a categorical and dose-\nresponse meta-analysis of prospective studies. Public Health Nutr. 2016:19(7):1233–44. doi:10.1017/S1368980015002463.\nQuality assessment\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nRelative \n(95% CI)\nPregnancy loss – very high caffeine intake vs very low or no caffeine intake\n4\nobserv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base tables (EB Table A.10c – 1 and 2) presenting non-randomized observational meta-analyses of maternal caffeine consumption and pregnancy loss. Part 1 (Chen et al., 2016) reports very-low-certainty odds ratios across low (OR 1.02), moderate (OR 1.16), high (OR 1.40), and very high (OR 1.72) caffeine intake versus very low/no intake due to funnel plot asymmetry; Part 2 (Li et al., 2015) reports moderate-certainty evidence (upgraded for a linear 19% risk increase per 150 mg/day caffeine) showing elevated pregnancy loss for any caffeine intake (18 studies; OR 1.32, 95% CI 1.24–1.40), moderate intake (OR 1.28), and high intake (OR 1.60), but not low intake (OR 1.04).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Maternal and fetal assessment",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../sections/sec-030-b-maternal-and-fetal-assessment.md",
      "narrative": null,
      "content": "B. Maternal and fetal assessment",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Part B (Maternal and fetal assessment) of the WHO antenatal care guideline evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Maternal assessment",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../sections/sec-031-b1-maternal-assessment.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.1.1a: Anaemia (test accuracy): haemoglobinometer method for diagnosing anaemia (Hb < 11 g/dL) in pregnancy",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../sections/sec-032-eb-table-b11a-anaemia-test-accuracy-haemoglobino.md",
      "narrative": null,
      "content": "Source: Sobhy S, Rogozinska E, Khan KS. Accuracy of on-site tests to detect anaemia in antenatal care: a systematic review. BJOG. 2016 (in press).\nPooled sensitivity: 0.85 (95% CI: 0.79–0.90); pooled specificity: 0.80 (95% CI: 0.76–0.83).\nTest result (anaemia is defined as Hb < 11 g/dL)\nNo. of results per 1000 women tested (95% CI)\nNo. of participants \n(studies)\nCertainty\nPrevalence 24%\nPrevalence 42%\nPrevalence 57%\nTrue positives (women with anaemia)\n204 (190 to 216)\n357 (332 to 378)\n484 (450 to 513)\n157 \n(1)\nMODERATE 1,2\nFalse negatives (women incorrectly classified as not having anaemia)\n36",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.1.1a) from the systematic review by Sobhy, Rogozinska, and Khan (2016) evaluating the diagnostic test accuracy of on-site haemoglobinometer testing for detecting anaemia (Hb < 11 g/dL) in pregnancy (1 study; 157 women with anaemia, 514 without). Reports a pooled sensitivity of 0.85 (95% CI 0.79–0.90) and pooled specificity of 0.80 (95% CI 0.76–0.83), with moderate certainty of evidence and anticipated true/false positive and negative counts per 1000 women tested at 24%, 42%, and 57% anaemia prevalence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.1.1b: Anaemia (test accuracy): Hb Colour Scale method for diagnosing anaemia (Hb < 11 g/dL) in pregnancy",
      "pageStart": 67,
      "pageEnd": 68,
      "target": "../sections/sec-033-eb-table-b11b-anaemia-test-accuracy-hb-colour-sc.md",
      "narrative": null,
      "content": "Source: Sobhy S, Rogozinska E, Khan KS. Accuracy of on-site tests to detect anaemia in antenatal care: a systematic review. BJOG. 2016 (in press).\nPooled sensitivity: 0.75 (95% CI: 0.71–0.80); pooled specificity: 0.47 (95% CI: 0.41–0.53).\nTest result (anaemia is defined as Hb < 11 g/dL)\nNo. of results per 1000 women tested (95% CI)\nNo. of participants \n(studies)\nCertainty\nPrevalence 24%\nPrevalence 42%\nPrevalence 57%\nTrue positives (women with anaemia)\n204 (190 to 216)\n357 (332 to 378)\n484 (450 to 513)\n157 \n(1)\nMODERATE 1,2\nFalse negatives (women incorrectly classified as not having anaemia)\n36",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.1.1b) from Sobhy, Rogozinska, and Khan (2016) assessing the diagnostic accuracy of the Haemoglobin (Hb) Colour Scale method for diagnosing anaemia (Hb < 11 g/dL) during pregnancy. Reports a pooled sensitivity of 0.75 (95% CI 0.71–0.80) and pooled specificity of 0.47 (95% CI 0.41–0.53) at moderate certainty, alongside illustrative true/false positive and negative counts per 1000 women across 24%, 42%, and 57% pre-test prevalence levels.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.1.2a: Asymptomatic bacteriuria (ASB): dipstick (nitrites or leukocytes) for diagnosing ASB in pregnancy",
      "pageStart": 68,
      "pageEnd": 68,
      "target": "../sections/sec-034-eb-table-b12a-asymptomatic-bacteriuria-asb-dipst.md",
      "narrative": null,
      "content": "EB Table B.1.2a: Asymptomatic bacteriuria (ASB): dipstick (nitrites or leukocytes) for diagnosing ASB in pregnancy\nSource: Rogozinska E, Formina S, Zamora J, Mignini L, Khan KS. Accuracy of on-site tests to detect asymptomatic bacteriuria in pregnancy: a systematic review and meta-analysis. Obstet Gynecol. 2016;128(3):495–503. \ndoi:10.1097/AOG.0000000000001597.\nPooled sensitivity: 0.73 (95% CI: 0.59–0.83); pooled specificity: 0.89 (95% CI: 0.79–0.94).\nTest result\nNo. of results per 1000 women tested (95% CI)\nNo. of participants \n(studies)\nCertainty\nPrevalence 3%\nPrevalence 9%\nPrevalence 19%\nTr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.1.2a) from Rogozinska et al. (2016) evaluating the diagnostic test accuracy of on-site urine dipstick testing (nitrites or leukocytes) for detecting asymptomatic bacteriuria (ASB) in pregnancy (7 studies; 603 women with ASB, 5087 without). Reports a pooled sensitivity of 0.73 (95% CI 0.59–0.83) and pooled specificity of 0.89 (95% CI 0.79–0.94) with very low certainty due to risk of bias, inconsistency, and imprecision, modelling true/false positive and negative rates per 1000 women at 3%, 9%, and 19% ASB prevalence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.1.2b: Asymptomatic bacteriuria (ASB): Gram staining for diagnosing ASB in pregnancy",
      "pageStart": 68,
      "pageEnd": 69,
      "target": "../sections/sec-035-eb-table-b12b-asymptomatic-bacteriuria-asb-gram.md",
      "narrative": null,
      "content": "Pooled sensitivity: 0.86 (95% CI: 0.80–0.91); pooled specificity: 0.97 (95% CI: 0.93–0.99).\nTest result\nNo. of results per 1000 women tested (95% CI)\nNo. of participants \n(studies)\nCertainty\nPrevalence 3%\nPrevalence 9%\nPrevalence 19%\nTrue positives (women with ASB)\n25 (23 to 27)\n76 (68 to 81)\n160 (143 to 171)\n156 \n(4)\n \nVERY LOW 1 ,2,3 \nFalse negatives (women incorrectly classified as not having ASB)\n5 (3 to 7)\n14 (9 to 22)\n30 (19 to 47)\nTrue negatives (women without ASB)\n951 (902 to 960)\n892 (846 to 901)\n794 (753 to 802)\n1748 \n(4)\n \nVERY LOW 1,2,4\nFalse positives (women incorrectly classified",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.1.2b) from Rogozinska et al. (2016) assessing the diagnostic accuracy of on-site Gram staining for diagnosing asymptomatic bacteriuria (ASB) in pregnancy (4 studies; 156 women with ASB, 1748 without). Reports a pooled sensitivity of 0.86 (95% CI 0.80–0.91) and pooled specificity of 0.97 (95% CI 0.93–0.99) with very low certainty of evidence, along with expected true/false positive and negative results per 1000 women tested at 3%, 9%, and 19% prevalence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.1.3: Intimate partner violence (IPV): screening women for IPV",
      "pageStart": 69,
      "pageEnd": 70,
      "target": "../sections/sec-036-eb-table-b13-intimate-partner-violence-ipv-scree.md",
      "narrative": null,
      "content": "EB Table B.1.3: Intimate partner violence (IPV): screening women for IPV\nSource: Rogozinska E, Formina S, Zamora J, Mignini L, Khan KS. Accuracy of on-site tests to detect asymptomatic bacteriuria in pregnancy: a systematic review and meta-analysis. Obstet Gynecol. 2016;128(3):495–503. \ndoi:10.1097/AOG.0000000000001597. \nOutcome\nNo. of \nparticipants \n(studies)\nAnticipated absolute effects\nRelative effect \n(95% CI)\nCertainty\nRisk with usual \nantenatal care\nRisk difference \nwith universal screening for IPV\nIdentification of IPV\n663 \n(2 RCTs)\n17 per 1000\n57 more per 1000 \n(13 more to 162 more)\nRR",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.1.3) evaluating universal antenatal screening for intimate partner violence (IPV) compared with usual antenatal care (2 RCTs, 663 participants). Shows that universal screening substantially increases identification of IPV (RR 4.28, 95% CI 1.77–10.36; 57 more per 1000 from a baseline of 17 per 1000; low certainty due to high risk of bias).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Fetal assessment",
      "pageStart": 70,
      "pageEnd": 71,
      "target": "../sections/sec-037-b2-fetal-assessment.md",
      "narrative": null,
      "content": "B.2. Fetal assessment\nEB Table B.2.1: Routine daily fetal movement counting versus usual practice (mixed or undefined fetal movement counting)\nSource: Mangesi L, Hofmeyr GJ, Smith V, Smyth RMD. Fetal movement counting for assessment of fetal wellbeing. Cochrane Database Syst Rev. 2015;(10):CD004909. \nOutcome\nNo. of \nparticipants \n(studies)\nAnticipated absolute effects*\nRelative effect \n(95% CI)\nCertainty\nRisk with mixed or undefined fetal \nmovement counting\nRisk difference with routine fetal \nmovement counting*\nCaesarean section\n1076 \n(1 RCT)\n71 per 1000\n5 fewer per 1000 \n(29 fewer to 31 more)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section B.2 heading (Fetal assessment) and EB Table B.2.1 from Mangesi et al. (2015) comparing routine daily fetal movement counting with usual practice (mixed or undefined counting; 1 RCT, 1076 participants). Reports low- to very-low-certainty GRADE evidence showing slightly lower maternal anxiety scores (1013 women; SMD -0.22, 95% CI -0.35 to -0.10; low certainty), no perinatal deaths in either group, and uncertain effects on caesarean section (RR 0.93), assisted vaginal birth (RR 1.04), preterm birth (RR 0.81), and low birth weight (RR 0.98).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.2.2: Symphysis-fundal height (SFH) measurement versus clinical palpation",
      "pageStart": 71,
      "pageEnd": 71,
      "target": "../sections/sec-038-eb-table-b22-symphysis-fundal-height-sfh-measure.md",
      "narrative": null,
      "content": "EB Table B.2.2: Symphysis-fundal height (SFH) measurement versus clinical palpation\nSource: Robert Peter J, Ho JJ, Valliapan J, Sivasangari S. Symphysial fundal height (SFH) measurement in pregnancy for detecting abnormal fetal growth. Cochrane Database Syst Rev. 2015;(9):CD008136. \nOutcome\nNo. of \nparticipants \n(studies)\nAnticipated absolute effects*\nRelative effect \n(95% CI)\nCertainty\nRisk with clinical palpation\nRisk difference with tape \nmeasurement\nCaesarean section\n1639 \n(1 RCT) \n16 per 1000\n4 fewer per 1000 \n(11 fewer to 10 more)\nRR 0.72 \n(0.31 to 1.67)\nLOW 1,2\nInduction of labour\n1639",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.2.2) from Robert Peter et al. (2015) comparing tape measurement of symphysis-fundal height (SFH) against clinical abdominal palpation for detecting abnormal fetal growth (1 RCT, 1639 participants). Reports GRADE evidence showing no clear difference in small for gestational age (RR 1.32, 95% CI 0.92–1.90; moderate certainty), caesarean section (RR 0.72, low certainty), induction of labour (RR 0.84, low certainty), or perinatal mortality (RR 1.25, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.2.3: Routine antenatal cardiotocography (CTG) versus no routine antenatal CTG",
      "pageStart": 71,
      "pageEnd": 72,
      "target": "../sections/sec-039-eb-table-b23-routine-antenatal-cardiotocography.md",
      "narrative": null,
      "content": "Source: Grivell RM, Alfirevic Z, Gyte GML, Devane D. Antenatal cardiotocography for fetal assessment. Cochrane Database Syst Rev. 2015;(9):CD007863. \nThere was no direct evidence on effects for this intervention.\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base entry (EB Table B.2.3) citing the Cochrane review by Grivell et al. (2015) on antenatal cardiotocography (CTG) for fetal assessment and noting that there was no direct randomized evidence on the effects of routine antenatal CTG versus no routine antenatal CTG in normal pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.2.4a: Early ultrasound scan (< 24 weeks of gestation) versus selective/concealed ultrasound scan in early pregnancy)",
      "pageStart": 72,
      "pageEnd": 73,
      "target": "../sections/sec-040-eb-table-b24a-early-ultrasound-scan-24-weeks-of.md",
      "narrative": null,
      "content": "EB Table B.2.4a: Early ultrasound scan (< 24 weeks of gestation) versus selective/concealed ultrasound scan in early \npregnancy)\nSource: Whitworth M, Bricker L, Mullan C. Ultrasound for fetal assessment in early pregnancy. Cochrane Database Syst Rev. 2015;(7):CD007058. \nOutcome\nNo. of \nparticipants \n(studies)\nAnticipated absolute effects*\nRelative effect \n(95% CI)\nCertainty\nRisk with selective/concealed \nultrasound in early pregnancy\nRisk difference with routine/\nrevealed\nCaesarean section\n22 193 \n(5 RCTs)\n132 per 1000\n7 more per 1000 \n(3 fewer to 16 more)\nRR 1.05 \n(0.98 to 1.12)\nMODERATE 1\nIn",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.2.4a) from Whitworth, Bricker, and Mullan (2015) comparing routine/revealed early ultrasound scan (< 24 weeks of gestation) with selective or concealed early ultrasound. Presents GRADE evidence showing reductions in labour induction for post-term pregnancy (8 RCTs, 25 516 women; RR 0.59, 95% CI 0.42–0.83; low certainty) and maternal dissatisfaction/worry (1 RCT, 634 women; RR 0.80; low certainty), marked increases in detection of major fetal anomalies before birth (2 RCTs, 387 women; RR 3.19; low certainty) and before 24 weeks (RR 3.46; low certainty), and little or no difference in caesarean section (RR 1.05, moderate certainty), small for gestational age (RR 1.05, moderate certainty), perinatal death (10 RCTs, 35 735 births; RR 0.89, low certainty), or low birth weight (RR 0.83, low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.2.4b: Late ultrasound scan (> 24 weeks of gestation) versus no, concealed or selective late ultrasound scan",
      "pageStart": 73,
      "pageEnd": 75,
      "target": "../sections/sec-041-eb-table-b24b-late-ultrasound-scan-24-weeks-of-g.md",
      "narrative": null,
      "content": "Source: Bricker L, Medley N, Pratt JJ. Routine ultrasound in late pregnancy (after 24 weeks of gestation). Cochrane Database Syst Rev. 2015;(6):CD001451. \nOutcome\nNo. of \nparticipants \n(studies)\nAnticipated absolute effects*\nRelative effect \n(95% CI)\nCertainty\nRisk with no/concealed/\nselective ultrasound\nRisk difference with routine \nultrasound\nCaesarean section\n22 663 \n(6 RCTs) \n139 per 1000\n4 more per 1000 \n(11 fewer to 21 more)\nRR 1.03 \n(0.92 to 1.15)\nMODERATE 1,2\nInduction of labour\n22 663 \n(6 RCTs) \n238 per 1000\n17 fewer per 1000 \n(45 fewer to 17 more)\nRR 0.93 \n(0.81 to 1.07)\nMODERATE 1\nI",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base tables (EB Table B.2.4b and EB Table B.2.5a) evaluating late pregnancy ultrasound (> 24 weeks; Bricker, Medley, and Pratt, 2015) and routine fetal/umbilical Doppler ultrasound in normal pregnancy (Alfirevic, Stampalija, and Medley, 2015). EB Table B.2.4b shows no clear difference between routine and no/concealed/selective late ultrasound across caesarean section (RR 1.03, moderate certainty), induction of labour (RR 0.93, moderate certainty), instrumental delivery (RR 1.05, moderate certainty), perinatal mortality (8 RCTs, 30 675 births; RR 1.01, moderate certainty), preterm birth (RR 0.96, moderate certainty), small for gestational age (RR 0.98, low certainty), or low birth weight. EB Table B.2.5a similarly shows no clear difference with all routine Doppler ultrasound versus no Doppler ultrasound in normal pregnancy for caesarean section (RR 0.98, moderate certainty), operative vaginal birth (RR 1.04, moderate certainty), perinatal death (4 RCTs, 11 183 births; RR 0.80, low certainty), or preterm birth (RR 1.02, moderate certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-042",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.2.5b: Multiple Doppler ultrasound versus no Doppler ultrasound in normal pregnancy",
      "pageStart": 75,
      "pageEnd": 76,
      "target": "../sections/sec-042-eb-table-b25b-multiple-doppler-ultrasound-versus.md",
      "narrative": null,
      "content": "EB Table B.2.5b: Multiple Doppler ultrasound versus no Doppler ultrasound in normal pregnancy \nOutcome\nNo. of \nparticipants \n(studies)\nAnticipated absolute effects\nRelative effect \n(95% CI)\nCertainty\nRisk with no Doppler ultrasound\nRisk difference with multiple \nDoppler ultrasound\nCaesarean section*\n2475 \n(1 RCT) \n75 per 1000\n1 fewer per 1000\n (19 fewer to 22 more)\nRR 0.98 \n(0.74 to 1.29)\nMODERATE 1\nOperative vaginal birth\nnot available\nnot available\nnot available\nnot available\nnot available\nPerinatal death\n7292 \n(3 RCTs) \n9 per 1000\n0 fewer per 1000 \n(6 fewer to 16 more)\nRR 1.04 \n(0.40 to 2.6",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.2.5b) from Alfirevic, Stampalija, and Medley (2015) comparing multiple Doppler ultrasound examinations versus no Doppler ultrasound in normal pregnancy. Reports GRADE evidence showing little or no difference in caesarean section for fetal/umbilical vessels plus uterine artery Doppler (1 RCT, 2475 women; RR 0.98, 95% CI 0.74–1.29; 1 fewer per 1000; moderate certainty), perinatal death (3 RCTs, 7292 births; RR 1.04, 95% CI 0.40–2.66; 0 fewer per 1000; low certainty), or preterm birth before 37 weeks (3 RCTs, 8264 women; RR 0.97, 95% CI 0.82–1.15; 2 fewer per 1000; moderate certainty), with operative vaginal birth data not available.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-043",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table B.2.5c: Single Doppler ultrasound versus no Doppler ultrasound in normal pregnancy",
      "pageStart": 76,
      "pageEnd": 77,
      "target": "../sections/sec-043-eb-table-b25c-single-doppler-ultrasound-versus-n.md",
      "narrative": null,
      "content": "EB Table B.2.5c: Single Doppler ultrasound versus no Doppler ultrasound in normal pregnancy\nOutcome\nNo. of \nparticipants \n(studies)\nAnticipated absolute effects\nRelative effect \n(95% CI)\nCertainty\nRisk with no Doppler ultrasound\nRisk difference with single Doppler \nultrasound\nCaesarean section\n3891 \n(1 RCT)\n129 per 1000\n1 fewer per 1000\n(21 fewer to 21 more)\nRR 0.99 \n(0.84 to 1.16)\nMODERATE 1\nOperative vaginal birth\n3891 \n(1 RCT)\n154 per 1000\n15 more per 1000 \n(8 fewer to 40 more)\nRR 1.10 \n(0.95 to 1.26)\nMODERATE 2\nPerinatal death\n3891 \n(1 RCT)\n7 per 1000\n5 fewer per 1000 \n(6 fewer to 0 fewer)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table B.2.5c) from Alfirevic, Stampalija, and Medley (2015) comparing a single Doppler ultrasound examination versus no Doppler ultrasound in normal pregnancy (1 RCT, 3891 women). Reports GRADE evidence indicating lower perinatal death with single Doppler ultrasound (RR 0.36, 95% CI 0.13–0.99; 5 fewer per 1000 from a 7 per 1000 baseline; low certainty), alongside little or no difference in caesarean section (RR 0.99, 95% CI 0.84–1.16; moderate certainty), operative vaginal birth (RR 1.10, 95% CI 0.95–1.26; moderate certainty), and preterm birth before 37 weeks (RR 1.20, 95% CI 0.86–1.69; very low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-044",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preventive measures",
      "pageStart": 77,
      "pageEnd": 77,
      "target": "../sections/sec-044-c-preventive-measures.md",
      "narrative": null,
      "content": "C. Preventive measures",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Part C (Preventive measures) of the WHO antenatal care guideline evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-045",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antibiotics for asymptomatic bacteriuria (ASB)",
      "pageStart": 77,
      "pageEnd": 77,
      "target": "../sections/sec-045-c1-antibiotics-for-asymptomatic-bacteriuria-asb.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-046",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table C.1: Antibiotics for ASB versus no treatment",
      "pageStart": 77,
      "pageEnd": 79,
      "target": "../sections/sec-046-eb-table-c1-antibiotics-for-asb-versus-no-treatm.md",
      "narrative": null,
      "content": "Source: Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2015;(8):CD000490.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAntibiotic \nNo treatment\nRelative\n(95% CI)\nAbsolute\nPyelonephritis – any antibiotic regimen\n11\nrandomized \ntrials\nvery serious1\nserious2\nno serious \nindirectness\nno serious \nimprecision\nnone\n55/983 \n(5.6%)\n197/949 \n(20.8%)\nRR 0.23 \n(0.13 to 0.41)\n160 fewer per 1000 \n(from 122 fewer to 181 fewer)\n \nVERY LOW\nPyelonephriti",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table C.1) from the Cochrane review by Smaill and Vazquez (2015) comparing antibiotic treatment for asymptomatic bacteriuria (ASB) in pregnancy against no treatment. Presents GRADE evidence showing reductions in maternal pyelonephritis across any antibiotic regimen (11 RCTs, 1932 women; RR 0.23, 95% CI 0.13–0.41; 160 fewer per 1000; very low certainty), single-dose therapy (1 RCT, 173 women; RR 0.44, 95% CI 0.21–0.92; low certainty), short-course 3–7 day therapy (3 RCTs, 483 women; RR 0.31, 95% CI 0.09–1.16; very low certainty), intermediate 3–6 week therapy (2 RCTs, 433 women; RR 0.17, 95% CI 0.08–0.37; very low certainty), and continuous antibiotic therapy (5 RCTs, 843 women; RR 0.16, 95% CI 0.04–0.57; very low certainty), as well as reductions in persistent bacteriuria (4 RCTs, 596 women; RR 0.30, 95% CI 0.18–0.53; 464 fewer per 1000; low certainty), birth weight < 2500 g (6 RCTs, 1437 births; RR 0.64, 95% CI 0.45–0.93; 49 fewer per 1000; low certainty), and preterm birth < 37 weeks (2 RCTs, 242 births; RR 0.27, 95% CI 0.11–0.62; 162 fewer per 1000; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-047",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antibiotic prophylaxis to prevent recurrent urinary tract infections (RUTI)",
      "pageStart": 79,
      "pageEnd": 79,
      "target": "../sections/sec-047-c2-antibiotic-prophylaxis-to-prevent-recurrent-u.md",
      "narrative": null,
      "content": "C.2. Antibiotic prophylaxis to prevent recurrent urinary tract infections (RUTI)",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section C.2 (Antibiotic prophylaxis to prevent recurrent urinary tract infections [RUTI]) in Part C of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-048",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table C.2: Antibiotic prophylaxis to prevent recurrent urinary tract infections (RUTI) versus control",
      "pageStart": 79,
      "pageEnd": 80,
      "target": "../sections/sec-048-eb-table-c2-antibiotic-prophylaxis-to-prevent-re.md",
      "narrative": null,
      "content": "Source: Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst Rev. 2015;(7):CD009279.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nNitrofurantoin \nand close \nsurveillance\nControl (close \nsurveillance \nalone)\nRelative\n(95% CI)\nAbsolute\nRecurrent pyelonephritis\n1\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nvery serious2,3\nnone\n6/82 \n(7.3%)\n7/85 \n(8.2%)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table C.2) from the Cochrane review by Schneeberger et al. (2015) comparing daily nitrofurantoin prophylaxis plus close clinic surveillance against close surveillance alone for preventing recurrent urinary tract infections (RUTI) during pregnancy (1 RCT). Reports GRADE evidence showing reduced asymptomatic bacteriuria among women with >= 90% clinic attendance (102 women; RR 0.55, 95% CI 0.34–0.89; 267 fewer per 1000; low certainty) and very low-certainty, imprecise estimates for recurrent pyelonephritis (167 women; RR 0.89, 95% CI 0.31–2.53), urinary tract infection/cystitis (167 women; RR 0.30, 95% CI 0.06–1.38), preterm birth < 37 weeks (147 women; RR 1.18, 95% CI 0.42–3.35), and low birth weight < 2500 g (147 women; RR 2.03, 95% CI 0.53–7.80).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-049",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antenatal anti-D immunoglobulin prophylaxis",
      "pageStart": 80,
      "pageEnd": 80,
      "target": "../sections/sec-049-c3-antenatal-anti-d-immunoglobulin-prophylaxis.md",
      "narrative": null,
      "content": "C.3. Antenatal anti-D immunoglobulin prophylaxis",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section C.3 (Antenatal anti-D immunoglobulin prophylaxis) in Part C of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-050",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table C.3: Antenatal anti-D immunoglobulin prophylaxis versus control",
      "pageStart": 80,
      "pageEnd": 82,
      "target": "../sections/sec-050-eb-table-c3-antenatal-anti-d-immunoglobulin-prop.md",
      "narrative": null,
      "content": "Source: McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunization. Cochrane Database Syst Rev. 2015;(9):CD000020.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAnti-D \nadministration in \npregnancy\nControl (no routine \nantenatal anti-D \nadministration)\nRelative\n(95% CI)\nAbsolute\nRhesus D alloimmunization during pregnancy – any regimen\n2\nrandomized \ntrials\nvery serious1,2\nno serious \ninconsistency\nno serious \nindirectness\nserious3\nnone\n5/1879 \n(",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table C.3) from the Cochrane review by McBain, Crowther, and Middleton (2015) comparing routine antenatal anti-D immunoglobulin prophylaxis in Rhesus-negative pregnant women against no routine antenatal anti-D administration. Presents GRADE evidence showing reduced positive Kleihauer fetomaternal haemorrhage tests at 32–35 weeks of gestation (1 RCT, 1884 women; RR 0.60, 95% CI 0.41–0.88; 28 fewer per 1000; low certainty) and at birth of an Rh-positive infant (1 RCT, 1189 women; RR 0.60, 95% CI 0.46–0.79; 81 fewer per 1000; low certainty), alongside very low-certainty estimates across overall, 100-microgram, and 50-microgram regimens (at 28 and 34 weeks) for Rhesus D alloimmunization during pregnancy (any regimen: 2 RCTs, 3902 women; RR 0.42, 95% CI 0.15–1.17), postpartum at birth of an Rh-positive infant (any regimen: 2 RCTs, 2297 women; RR 0.42, 95% CI 0.15–1.17), postpartum through 12 months of follow-up (any regimen: 2 RCTs, 2048 women; RR 0.39, 95% CI 0.10–1.62; primigravidae at 2–12 months: 1 RCT, 722 women; RR 0.11, 95% CI 0.01–2.04), and neonatal jaundice (1 RCT, 1882 neonates; RR 0.26, 95% CI 0.03–2.30).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-051",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preventive anthelminthic treatment",
      "pageStart": 82,
      "pageEnd": 82,
      "target": "../sections/sec-051-c4-preventive-anthelminthic-treatment.md",
      "narrative": null,
      "content": "C.4. Preventive anthelminthic treatment",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section C.4 (Preventive anthelminthic treatment) in Part C of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-052",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table C.4: Preventive anthelminthic treatment versus control",
      "pageStart": 82,
      "pageEnd": 83,
      "target": "../sections/sec-052-eb-table-c4-preventive-anthelminthic-treatment-v.md",
      "narrative": null,
      "content": "Source: Salam RA, Haider BA, Humayun Q, Bhutta ZA. Effect of administration of anthelminthics for soil-transmitted helminths during pregnancy. Cochrane Database Syst Rev. 2015;(6):CD005547.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAntihelminthics\nControl \n(no routine \nanthelminthics)\nRelative\n(95% CI)\nAbsolute\nMaternal anaemia in third trimester (< 110 g/L)\n4\nrandomized \ntrials\nserious1\nserious2\nno serious \nindirectness\nno serious \nimprecision\nnone\n715/2121 \n(33.7%)\n390/1145 \n(34.1%)\nRR 0.9",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table C.4) from the Cochrane review by Salam et al. (2015) evaluating preventive anthelminthic administration for soil-transmitted helminths during pregnancy versus no routine anthelminthics. Reports GRADE evidence showing little or no difference in third-trimester maternal anaemia (< 110 g/L; 4 RCTs, 3266 women; RR 0.94, 95% CI 0.81–1.10; 20 fewer per 1000; low certainty), low birth weight (3 RCTs, 3255 births; RR 1.00, 95% CI 0.79–1.27; moderate certainty), preterm birth (2 RCTs, 1318 births; RR 0.88, 95% CI 0.43–1.78; very low certainty), or perinatal mortality (2 RCTs, 3385 births; RR 1.09, 95% CI 0.71–1.67; moderate certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-053",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Tetanus toxoid vaccination",
      "pageStart": 83,
      "pageEnd": 83,
      "target": "../sections/sec-053-c5-tetanus-toxoid-vaccination.md",
      "narrative": null,
      "content": "C.5. Tetanus toxoid vaccination",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section C.5 (Tetanus toxoid vaccination) in Part C of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-054",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table C.5: Tetanus toxoid (TT) vaccination versus influenza vaccination",
      "pageStart": 83,
      "pageEnd": 84,
      "target": "../sections/sec-054-eb-table-c5-tetanus-toxoid-tt-vaccination-versus.md",
      "narrative": null,
      "content": "Source: Demicheli V, Barale A, Rivetti A. Vaccines for women for preventing neonatal tetanus. Cochrane Database Syst Rev. 2015;(7):CD002959.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nTT vaccine\nInfluenza vaccine\nRelative\n(95% CI)\nAbsolute\nNeonatal tetanus cases – any dose\n1\nrandomized \ntrials\nserious1\nserious2\nno serious \nindirectness\nserious3\nnone\n9/565 \n(1.6%)\n49/617 \n(7.9%)\nRR 0.2 \n(0.1 to 0.4) \n64 fewer per 1000 \n(from 48 fewer to 71 fewer)\nLOW\nNeonatal tetanus deaths – one dose\n1\nrandom",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table C.5) from the Cochrane review by Demicheli, Barale, and Rivetti (2015) comparing maternal tetanus toxoid (TT) vaccination with influenza vaccination control for preventing neonatal tetanus (1 RCT). Summarizes GRADE evidence demonstrating substantial reductions in neonatal tetanus cases with any TT dose (1182 infants; RR 0.20, 95% CI 0.10–0.40; 64 fewer per 1000; low certainty), neonatal tetanus deaths after two or three doses (688 infants; RR 0.02, 95% CI 0.00–0.30; 76 fewer per 1000; low certainty), and all-cause neonatal deaths after two or three doses (688 infants; RR 0.31, 95% CI 0.17–0.55; 91 fewer per 1000; moderate certainty), while single-dose estimates for neonatal tetanus deaths (494 infants; RR 0.57, 95% CI 0.26–1.24; very low certainty) and all-cause deaths (494 infants; RR 1.08, 95% CI 0.65–1.79; low certainty) were imprecise.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-055",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Interventions for common physiological symptoms",
      "pageStart": 84,
      "pageEnd": 84,
      "target": "../sections/sec-055-d-interventions-for-common-physiological-symptom.md",
      "narrative": null,
      "content": "D. Interventions for common physiological symptoms",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Part D (Interventions for common physiological symptoms) of the WHO antenatal care guideline evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-056",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Nausea and vomiting",
      "pageStart": 84,
      "pageEnd": 84,
      "target": "../sections/sec-056-d1-nausea-and-vomiting.md",
      "narrative": null,
      "content": "Source: Matthews A, Haas DM, O’Mathúna DP, Dowswell T. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2015;(9):CD007575.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading and source citation for Section D.1 (Nausea and vomiting), citing the Cochrane review by Matthews et al. (2015) on interventions for nausea and vomiting in early pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-057",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1a: P6 acupressure versus placebo",
      "pageStart": 84,
      "pageEnd": 85,
      "target": "../sections/sec-057-eb-table-d1a-p6-acupressure-versus-placebo.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nP6 \nacupressure\nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nSeverity of nausea after treatment (of 4 days) using a 10 cm visual analogue scale (VAS; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nvery serious2\nnone\n50\n50\nMD 1.7 lower \n(2.41 to 0.99 lower)\n-\nLOW\nNo improvement in intensity of symptoms\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1a) from Matthews et al. (2015) comparing P6 (Neiguan) acupressure with placebo for nausea and vomiting in early pregnancy. Reports GRADE evidence from single-trial comparisons showing lower nausea severity on a 10 cm visual analogue scale (VAS) after 4 days of treatment (100 women; MD 1.70 lower, 95% CI 2.41–0.99 lower; low certainty) and fewer vomiting episodes after 4 days (100 women; MD 0.90 lower, 95% CI 1.06–0.74 lower; low certainty), alongside uncertain or non-significant effects on failure to improve symptom intensity (97 women; RR 0.78, 95% CI 0.44–1.39; low certainty), mean VAS nausea after day 3 (40 women; MD 0.10 higher; low certainty) or averaged over days 1–3 (60 women; MD 0.39 higher; very low certainty), mean Rhodes Index total scores on days 1–3 (60 women; MD 1.17 higher; very low certainty) or day 3 (93 women; MD 1.48 lower; very low certainty), and mean emesis scores on days 1–3 (60 women; MD 0.26 higher; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-058",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1b: Auricular acupressure versus placebo",
      "pageStart": 85,
      "pageEnd": 86,
      "target": "../sections/sec-058-eb-table-d1b-auricular-acupressure-versus-placeb.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAuricular \nacupressure \nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nNausea/vomiting score (combined Rhodes Index score) on day 6 (3 days after treatment started) (MD; better indicated by lower values)\n1\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nserious\nnone\n45\n46\nMD 3.6 lower \n(6.62 to 0.58 lower)\n-\nLOW\n1.\t\nBaseline imbalance in scores favouring intervention group and unblinded [–2].\nWeb supplement: \nWHO re",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1b) from Matthews et al. (2015) comparing auricular acupressure against placebo for nausea and vomiting in early pregnancy (1 RCT, 91 women). Reports low-certainty GRADE evidence (downgraded for baseline score imbalance, lack of blinding, and small sample size) of a lower combined Rhodes Index nausea/vomiting score on day 6 (3 days after starting treatment; MD 3.60 lower, 95% CI 6.62–0.58 lower).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-059",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1c: Acustimulation therapy at P6 point versus placebo",
      "pageStart": 86,
      "pageEnd": 86,
      "target": "../sections/sec-059-eb-table-d1c-acustimulation-therapy-at-p6-point.md",
      "narrative": null,
      "content": "EB Table D.1c: Acustimulation therapy at P6 point versus placebo\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAcustimulation \ntherapy \nat P6 point\nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nWeight gain (in lbs) over 3 week period (MD; better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nserious1\nserious2\nnone\n95\n92\nMD 1.7 higher \n(0.23 to 3.17 higher)\n-\nLOW\nDehydration: occurrences reported\n1\nrandomized \ntrials\nno serious risk \nof bias\nno",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1c) from Matthews et al. (2015) comparing acustimulation therapy at the P6 point against placebo in early pregnancy (1 RCT, 187 women). Presents low-certainty GRADE evidence (downgraded for outcome indirectness and imprecision) showing greater maternal weight gain over a 3-week period (MD 1.70 lbs higher, 95% CI 0.23–3.17 higher) and fewer reported occurrences of dehydration (RR 0.24, 95% CI 0.07–0.83; 99 fewer per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-060",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1d: Traditional acupuncture versus placebo",
      "pageStart": 86,
      "pageEnd": 87,
      "target": "../sections/sec-060-eb-table-d1d-traditional-acupuncture-versus-plac.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nTraditional \nacupuncture\nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nMean nausea score on day 7 (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n148\n148\nMD 0.7 lower \n(1.36 to 0.04 lower)\n-\nLOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (i.e. < 40%) from studies “C”. \n2.\t Small sample size.\nWeb supplement: \nWHO rec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1d) from Matthews et al. (2015) comparing traditional acupuncture against placebo for nausea and vomiting in early pregnancy (1 RCT, 296 women). Reports low-certainty GRADE evidence of a slightly lower mean nausea score on day 7 (MD 0.70 lower, 95% CI 1.36–0.04 lower).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-061",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1e: P6 acupuncture versus placebo",
      "pageStart": 87,
      "pageEnd": 88,
      "target": "../sections/sec-061-eb-table-d1e-p6-acupuncture-versus-placebo.md",
      "narrative": null,
      "content": "EB Table D.1e: P6 acupuncture versus placebo \nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nP6 acupuncture\nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nMean nausea score on day 7 (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n148\n148\nMD 0.3 lower \n(1 lower to 0.4 higher)\n-\nLOW\nMean dry retching score on day 7 (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno ser",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1e) from Matthews et al. (2015) comparing P6 acupuncture against placebo for nausea and vomiting in early pregnancy (1 RCT, 296 women). Reports low-certainty GRADE evidence showing no clear difference on day 7 in mean nausea score (MD 0.30 lower, 95% CI 1.00 lower to 0.40 higher), mean dry retching score (MD 0.10 higher, 95% CI 0.30 lower to 0.50 higher), or mean vomiting score (MD 0.30 lower, 95% CI 0.78 lower to 0.18 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-062",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1f: Ginger versus placebo",
      "pageStart": 88,
      "pageEnd": 89,
      "target": "../sections/sec-062-eb-table-d1f-ginger-versus-placebo.md",
      "narrative": null,
      "content": "EB Table D.1f: Ginger versus placebo \nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nGinger\nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nMean nausea score (using Rhodes Index) on day 3 (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n34\n34\nMD 1.38 lower \n(2.73 to 0.03 lower)\n-\nLOW\nMean vomiting score (using Rhodes Index) on day 3 (better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \nincons",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1f) from Matthews et al. (2015) comparing ginger with placebo for nausea and vomiting in early pregnancy. Summarizes GRADE evidence from single-trial comparisons showing improvements with ginger across mean Rhodes Index nausea score on day 3 (68 women; MD 1.38 lower, 95% CI 2.73–0.03 lower; low certainty), mean Rhodes Index vomiting score on day 3 (68 women; MD 1.14 lower, 95% CI 1.91–0.37 lower; low certainty), total Rhodes Index score on day 3 (68 women; MD 2.52 lower, 95% CI 4.50–0.54 lower; low certainty) and after 1 week of treatment (70 women; MD 4.19 lower, 95% CI 6.65–1.73 lower; low certainty), fewer women with little improvement in nausea (23 women; RR 0.29, 95% CI 0.10–0.82; 568 fewer per 1000; moderate certainty), and fewer women continuing to vomit at day 6 (22 women; RR 0.42, 95% CI 0.18–0.98; 464 fewer per 1000; moderate certainty), alongside a low-certainty estimate for overall symptom improvement (62 women; RR 1.25, 95% CI 0.96–1.63).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-063",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1g: Lemon oil versus placebo",
      "pageStart": 89,
      "pageEnd": 89,
      "target": "../sections/sec-063-eb-table-d1g-lemon-oil-versus-placebo.md",
      "narrative": null,
      "content": "EB Table D.1g: Lemon oil versus placebo \nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nLemon oil \nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nMean nausea and vomiting (PUQE) score on day 3 of intervention (better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nvery serious1,2\nnone\n50\n50\nMD 0.46 lower \n(1.27 lower to 0.35 higher)\n-\nLOW\nTotal nausea and vomiting (PUQE) scores from baseline to day 3 of intervention (bette",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1g) from Matthews et al. (2015) comparing lemon oil inhalation against placebo for nausea and vomiting in early pregnancy (1 RCT, 100 women). Reports low-certainty GRADE evidence showing a lower total Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) score from baseline to day 3 (MD 1.50 lower, 95% CI 2.41–0.59 lower), but imprecise differences in mean PUQE score on day 3 alone (MD 0.46 lower, 95% CI 1.27 lower to 0.35 higher) and maternal satisfaction with treatment (RR 1.47, 95% CI 0.91–2.37).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-064",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1h: Mint oil versus placebo",
      "pageStart": 89,
      "pageEnd": 90,
      "target": "../sections/sec-064-eb-table-d1h-mint-oil-versus-placebo.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nMint oil \nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nSeverity of nausea on day 4 (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2,3\nnone\n30\n30\nMD 0.88 lower \n(1.93 lower to 0.17 higher)\n-\n \nVERY LOW\nVomiting intensity on day 4 (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2,3\nnone\n30\n30\nMD",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1h) from Matthews et al. (2015) comparing mint oil against placebo for nausea and vomiting in early pregnancy (1 RCT, 60 women). Reports very low-certainty GRADE evidence showing no clear difference on day 4 in nausea severity (MD 0.88 lower, 95% CI 1.93 lower to 0.17 higher) or vomiting intensity (MD 0.32 lower, 95% CI 1.45 lower to 0.81 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-065",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1i: Chamomile versus placebo",
      "pageStart": 90,
      "pageEnd": 90,
      "target": "../sections/sec-065-eb-table-d1i-chamomile-versus-placebo.md",
      "narrative": null,
      "content": "EB Table D.1i: Chamomile versus placebo\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nChamomile\nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nRhodes Index score after 1 week treatment (Better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n35\n35\nMD 5.74 lower \n(8.31 to 3.17 lower)\n-\nLOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (i.e. < 40%) from studies “C”",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1i) from Matthews et al. (2015) comparing chamomile against placebo for nausea and vomiting in early pregnancy (1 RCT, 70 women). Reports low-certainty GRADE evidence of a lower Rhodes Index score after 1 week of treatment with chamomile (MD 5.74 lower, 95% CI 8.31–3.17 lower).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-066",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1j: Vitamin B6 versus placebo",
      "pageStart": 90,
      "pageEnd": 91,
      "target": "../sections/sec-066-eb-table-d1j-vitamin-b6-versus-placebo.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nVitamin B6 \nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nMean reduction in nausea score after 3 days (better indicated by lower values)\n2\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone1\n199\n194\nMD 0.92 higher \n(0.4 to 1.44 higher)\n-\nMODERATE\nNumber of women with emesis post-therapy\n2\nrandomized \ntrials\nno serious risk \nof bias\nserious2\nno serious \nindirectness\nserious3\nnone",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1j) from Matthews et al. (2015) comparing oral vitamin B6 (pyridoxine) against placebo for nausea and vomiting in early pregnancy (2 RCTs). Reports GRADE evidence showing a greater mean reduction in nausea score after 3 days of vitamin B6 therapy (393 women; MD 0.92 higher reduction, 95% CI 0.40–1.44 higher; moderate certainty), but no clear reduction in the number of women with post-therapy emesis (392 women; RR 0.76, 95% CI 0.35–1.66; 88 fewer per 1000; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-067",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1k: P6 acupressure versus vitamin B6",
      "pageStart": 91,
      "pageEnd": 91,
      "target": "../sections/sec-067-eb-table-d1k-p6-acupressure-versus-vitamin-b6.md",
      "narrative": null,
      "content": "EB Table D.1k: P6 acupressure versus vitamin B6  \nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nP6 acupressure\nControl \n(vitamin B6)\nRelative\n(95% CI)\nAbsolute\nNausea scores on day 3 (better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nvery serious1,2\nnone\n33\n33\nMD 0.2 higher \n(2.24 lower to 2.64 higher)\n-\nLOW\nPoor symptom relief/amount of rescue medication (number of tablets; better indicated by lower values)\n1\nrando",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1k) from Matthews et al. (2015) comparing P6 acupressure directly against vitamin B6 for nausea and vomiting in early pregnancy (1 RCT). Reports GRADE evidence showing no clear difference in day-3 nausea scores (66 women; MD 0.20 higher, 95% CI 2.24 lower to 2.64 higher; low certainty), but fewer tablets of rescue medication required for poor symptom relief with P6 acupressure (60 women; MD 2.20 lower, 95% CI 3.98–0.42 lower; moderate certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-068",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1l: Traditional acupuncture versus P6 acupuncture",
      "pageStart": 91,
      "pageEnd": 92,
      "target": "../sections/sec-068-eb-table-d1l-traditional-acupuncture-versus-p6-a.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nTraditional \nacupuncture\nControl \n(P6 acupuncture)\nRelative\n(95% CI)\nAbsolute\nMean nausea score on day 7 (better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nvery serious1,2\nnone\n148\n148\nMD 0.4 lower \n(1.12 lower to 0.32 higher)\n-\nLOW\nMean dry retching score on day 7 (better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1l) from Matthews et al. (2015) comparing traditional acupuncture directly against P6 acupuncture for nausea and vomiting in early pregnancy (1 RCT, 296 women). Reports low-certainty GRADE evidence showing no clear difference on day 7 in mean nausea score (MD 0.40 lower, 95% CI 1.12 lower to 0.32 higher), mean dry retching score (MD 0.30 lower, 95% CI 0.65 lower to 0.05 higher), or mean vomiting score (MD 0.20 higher, 95% CI 0.26 lower to 0.66 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-069",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1m: Ginger versus P6 acupressure",
      "pageStart": 92,
      "pageEnd": 92,
      "target": "../sections/sec-069-eb-table-d1m-ginger-versus-p6-acupressure.md",
      "narrative": null,
      "content": "EB Table D.1m: Ginger versus P6 acupressure\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nGinger versus P6 \nacupressure\nControl\nRelative\n(95% CI)\nAbsolute\nTotal Rhodes Index score on the 3rd day of intervention (better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nvery serious1,2\nnone\n50\n48\nMD 2.27 higher \n(0.01 lower to 4.55 higher)\n-\nLOW\n1.\t\nWide CI crossing the line of no effect.\n2.\t Small sample size.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1m) from Matthews et al. (2015) comparing ginger against P6 acupressure for nausea and vomiting in early pregnancy (1 RCT, 98 women). Reports low-certainty GRADE evidence of no clear difference in total Rhodes Index score on the 3rd day of intervention (MD 2.27 higher with ginger, 95% CI 0.01 lower to 4.55 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-070",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1n: Ginger versus chamomile",
      "pageStart": 92,
      "pageEnd": 93,
      "target": "../sections/sec-070-eb-table-d1n-ginger-versus-chamomile.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nGinger \nChamomile \nRelative\n(95% CI)\nAbsolute\nRhodes Index score after 1 week treatment (better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n35\n35\nMD 1.55 higher \n(0.34 lower to 3.44 higher)\n-\nLOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (i.e. < 40%) from studies “C”. \n2.\t Wide CI crossing the line of no effect.\nWeb supple",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1n) from Matthews et al. (2015) comparing ginger against chamomile for nausea and vomiting in early pregnancy (1 RCT, 70 women). Reports low-certainty GRADE evidence showing no clear difference in Rhodes Index score after 1 week of treatment (MD 1.55 higher with ginger, 95% CI 0.34 lower to 3.44 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-071",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1o: Ginger versus vitamin B6",
      "pageStart": 93,
      "pageEnd": 94,
      "target": "../sections/sec-071-eb-table-d1o-ginger-versus-vitamin-b6.md",
      "narrative": null,
      "content": "EB Table D.1o: Ginger versus vitamin B6 \nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nGinger\n Vitamin B6\nRelative\n(95% CI)\nAbsolute\nNausea vomiting score day 3 (better indicated by lower values)\n2\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nvery serious1,2\nnone\n125\n126\nSMD 0 higher \n(0.25 lower to 0.25 higher)\n-\nLOW\nNausea vomiting score day 3 – Rhodes Index (better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno ser",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1o) from Matthews et al. (2015) comparing ginger directly against vitamin B6 for nausea and vomiting in early pregnancy. Summarizes low-certainty GRADE evidence showing little or no difference between ginger and vitamin B6 in pooled day-3 nausea and vomiting scores (2 RCTs, 251 women; SMD 0.00, 95% CI -0.25 to 0.25), day-3 Rhodes Index score (1 RCT, 123 women; SMD 0.09 lower, 95% CI -0.44 to 0.27), day-3 10 cm VAS score (1 RCT, 128 women; SMD 0.08 higher, 95% CI -0.27 to 0.43), day-3 post-treatment vomiting episodes (1 RCT, 128 women; MD 0.00, 95% CI -0.60 to 0.60), or lack of symptom improvement (2 RCTs, 360 women; RR 0.84, 95% CI 0.47–1.52).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-072",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1p: Vitamin B6 (high dose) versus vitamin B6 (low dose)",
      "pageStart": 94,
      "pageEnd": 94,
      "target": "../sections/sec-072-eb-table-d1p-vitamin-b6-high-dose-versus-vitamin.md",
      "narrative": null,
      "content": "EB Table D.1p: Vitamin B6 (high dose) versus vitamin B6 (low dose)\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nVitamin B6 \n(high dose) \nVitamin B6 \n(low dose)\nRelative\n(95% CI)\nAbsolute\nMean change in PUQE score from baseline to 2 weeks (better indicated by lower values)\n1\nrandomized \ntrials\nserious\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n30\n30\nMD 1.06 lower \n(2.05 to 0.07 lower)\n-\nLOW\nPUQE: pregnancy-unique quantification of emesis/nausea",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1p) from Matthews et al. (2015) comparing high-dose versus low-dose vitamin B6 for nausea and vomiting in early pregnancy (1 RCT, 60 women). Reports low-certainty GRADE evidence of a slightly greater reduction in PUQE score from baseline to 2 weeks with high-dose vitamin B6 (MD 1.06 lower, 95% CI 2.05–0.07 lower).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-073",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1q: Ginger versus metoclopramide",
      "pageStart": 94,
      "pageEnd": 95,
      "target": "../sections/sec-073-eb-table-d1q-ginger-versus-metoclopramide.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nGinger \nMetoclopramide\nRelative\n(95% CI)\nAbsolute\nMean score for nausea (using Rhodes Index) on day 3 (better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n34\n34\nMD 1.56 higher \n(0.22 lower to 3.34 higher)\n-\nLOW\nMean score for vomiting (using Rhodes Index) on day 3 (better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectn",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1q) from Matthews et al. (2015) comparing ginger against metoclopramide for nausea and vomiting in early pregnancy (1 RCT, 68 women). Reports low-certainty GRADE evidence showing no clear difference on day 3 in mean Rhodes Index nausea score (MD 1.56 higher with ginger, 95% CI 0.22 lower to 3.34 higher), mean vomiting score (MD 0.33 higher, 95% CI 0.69 lower to 1.35 higher), or total Rhodes Index score (MD 1.89 higher, 95% CI 0.78 lower to 4.56 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-074",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1r: Doxylamine and pyridoxine versus placebo",
      "pageStart": 95,
      "pageEnd": 95,
      "target": "../sections/sec-074-eb-table-d1r-doxylamine-and-pyridoxine-versus-pl.md",
      "narrative": null,
      "content": "EB Table D.1r: Doxylamine and pyridoxine versus placebo \nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nDoxylamine \nand pyridoxine \nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nMean difference in nausea/vomiting/retching (PUQE score) baseline to day 15 (better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n131\n125\nMD 0.9 lower \n(1.55 to 0.25 lower)\n-\nMODERATE\nHeadache\n1\nrandomized \ntrials\nno serious risk",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1r) from Matthews et al. (2015) comparing combined doxylamine and pyridoxine (vitamin B6) against placebo for nausea and vomiting in early pregnancy (1 RCT, 256 women). Reports GRADE evidence showing a greater improvement in nausea, vomiting, and retching on the PUQE scale from baseline to day 15 (MD 0.90 lower, 95% CI 1.55–0.25 lower; moderate certainty), with no clear difference in maternal headache (RR 0.81, 95% CI 0.45–1.48; low certainty) or somnolence (RR 1.21, 95% CI 0.64–2.27; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-075",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1s: Metoclopramide versus placebo",
      "pageStart": 95,
      "pageEnd": 96,
      "target": "../sections/sec-075-eb-table-d1s-metoclopramide-versus-placebo.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nMetoclopramide\nControl \n(placebo)\nRelative\n(95% CI)\nAbsolute\nMean score for nausea (using Rhodes Index) on day 3 (better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n34\n34\nMD 2.94 lower \n(4.55 to 1.33 lower)\n-\nMODERATE\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (i.e. < 40%) from studies “C”.\nWeb supplement: \nW",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1s) from Matthews et al. (2015) comparing metoclopramide against placebo for nausea and vomiting in early pregnancy (1 RCT, 68 women). Reports moderate-certainty GRADE evidence of a lower mean Rhodes Index nausea score on day 3 with metoclopramide (MD 2.94 lower, 95% CI 4.55–1.33 lower).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-076",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1t: Ondansetron versus metoclopramide",
      "pageStart": 96,
      "pageEnd": 96,
      "target": "../sections/sec-076-eb-table-d1t-ondansetron-versus-metoclopramide.md",
      "narrative": null,
      "content": "EB Table D.1t: Ondansetron versus metoclopramide\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nOndansetron\nMetoclopramide\nRelative\n(95% CI)\nAbsolute\nAverage number of nausea episodes on day 3 after treatment (better indicated by lower values)\n1\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n35\n35\nMD 0.12 lower \n(0.44 lower to 0.2 higher)\n-\n \nVERY LOW\nAverage number of vomiting episodes on day 3 after treatment (better indicated by lower values)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1t) from Matthews et al. (2015) comparing ondansetron against metoclopramide for nausea and vomiting in early pregnancy (1 RCT, 70 women). Reports very low-certainty GRADE evidence showing no clear difference on day 3 after treatment in average nausea episodes (MD 0.12 lower, 95% CI 0.44 lower to 0.20 higher) or average vomiting episodes (MD 0.20 lower, 95% CI 0.57 lower to 0.17 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-077",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.1u: Ondansetron versus pyridoxine-doxylamine",
      "pageStart": 96,
      "pageEnd": 97,
      "target": "../sections/sec-077-eb-table-d1u-ondansetron-versus-pyridoxine-doxyl.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nOndansetron\nPyridoxine-\ndoxylamine \nRelative\n(95% CI)\nAbsolute\nClinically significant ( 25 mm on VAS) reduction in nausea after 5 days of treatment\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n12/13 \n(92.3%)\n7/17 \n(41.2%)\nRR 2.24 \n(1.24 to 4.04)\n511 more per 1000 \n(from 99 more to 1000 more)\nLOW\nSedation\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.1u) from Matthews et al. (2015) comparing ondansetron against combined pyridoxine–doxylamine for nausea and vomiting in early pregnancy (1 RCT, 30 women). Reports low-certainty GRADE evidence of a higher rate of clinically significant (>= 25 mm VAS) nausea reduction after 5 days with ondansetron (RR 2.24, 95% CI 1.24–4.04; 511 more per 1000) and imprecise differences in sedation (RR 0.75, 95% CI 0.28–2.02) and constipation (RR 2.18, 95% CI 0.63–7.50).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-078",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Interventions for heartburn",
      "pageStart": 97,
      "pageEnd": 97,
      "target": "../sections/sec-078-d2-interventions-for-heartburn.md",
      "narrative": null,
      "content": "D.2. Interventions for heartburn\nSource: Phupong V, Hanprasertpong T. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. 2015;(9):CD011379.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading and source citation for Section D.2 (Interventions for heartburn), citing the Cochrane review by Phupong and Hanprasertpong (2015) on interventions for heartburn in pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-079",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.2a: Any pharmacological treatment versus placebo or no treatment",
      "pageStart": 97,
      "pageEnd": 98,
      "target": "../sections/sec-079-eb-table-d2a-any-pharmacological-treatment-versu.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAny \npharmacological \ntreatment \nControl \n(placebo or \nno treatment)\nRelative\n(95% CI)\nAbsolute\nComplete relief of heartburn\n2\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n75/133 \n(56.4%)\n37/123 \n(30.1%)\nRR 1.85 \n(1.36 to 2.5)\n256 more per 1000 \n(from 108 more to 451 more)\nMODERATE\nPartial relief of heartburn\n2\nrandomized \ntrials\nserious1\nserious2\nno serious \nindirectness\nserious3\nnone\n40",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.2a) from the Cochrane review by Phupong and Hanprasertpong (2015) comparing any pharmacological treatment for heartburn in pregnancy against placebo or no treatment (2 RCTs, 256 women). Reports GRADE evidence showing increased complete relief of heartburn with pharmacological therapy (RR 1.85, 95% CI 1.36–2.50; 256 more per 1000; moderate certainty), with very low-certainty, imprecise estimates for partial heartburn relief (RR 1.35, 95% CI 0.38–4.76) and maternal side-effects (RR 0.63, 95% CI 0.21–1.89).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-080",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.2b: Pharmacological treatment versus lifestyle change",
      "pageStart": 98,
      "pageEnd": 98,
      "target": "../sections/sec-080-eb-table-d2b-pharmacological-treatment-versus-li.md",
      "narrative": null,
      "content": "EB Table D.2b: Pharmacological treatment versus lifestyle change\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nPharmacological \ntreatment\nLifestyle \nchange\nRelative\n(95% CI)\nAbsolute\nComplete relief of heartburn\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious \nnone\n37/41 \n(90.2%)\n9/24 \n(37.5%)\nRR 2.41 \n(1.42 to 4.07)\n529 more per 1000 \n(from 157 more to 1000 more)\nLOW\nSide-effects\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.2b) from Phupong and Hanprasertpong (2015) comparing pharmacological treatment against lifestyle modification for heartburn in pregnancy (1 RCT). Reports GRADE evidence showing higher complete relief of heartburn with pharmacological treatment (65 women; RR 2.41, 95% CI 1.42–4.07; 529 more per 1000; low certainty) and very low-certainty evidence on side-effects (66 women; RR 1.74, 95% CI 0.07–41.21).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-081",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.2c: Acupuncture versus no treatment",
      "pageStart": 98,
      "pageEnd": 99,
      "target": "../sections/sec-081-eb-table-d2c-acupuncture-versus-no-treatment.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAcupuncture \nControl \n(no treatment)\nRelative\n(95% CI)\nAbsolute\nQuality of life – improvement in the ability to sleep\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n14/20 \n(70%)\n4/16 \n(25%)\nRR 2.8 \n(1.14 to 6.86)\n450 more per 1000 \n(from 35 more to 1000 more)\nLOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (i.e. < 40%) from studies “C”.\n2.\t Small sample",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.2c) from Phupong and Hanprasertpong (2015) comparing acupuncture against no treatment for heartburn in pregnancy (1 RCT, 36 women). Reports low-certainty GRADE evidence of improved quality of life measured as ability to sleep with acupuncture (RR 2.80, 95% CI 1.14–6.86; 450 more per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-082",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Interventions for leg cramps",
      "pageStart": 99,
      "pageEnd": 99,
      "target": "../sections/sec-082-d3-interventions-for-leg-cramps.md",
      "narrative": null,
      "content": "D.3. Interventions for leg cramps\nSource: Zhou K, West HM, Zhang J, Xu L, Li W. Interventions for leg cramps in pregnancy. Cochrane Database Syst Rev. 2015;(8):CD010655.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading and source citation for Section D.3 (Interventions for leg cramps), citing the Cochrane review by Zhou et al. (2015) on interventions for leg cramps in pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-083",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.3a: Oral magnesium versus placebo or no treatment",
      "pageStart": 99,
      "pageEnd": 101,
      "target": "../sections/sec-083-eb-table-d3a-oral-magnesium-versus-placebo-or-no.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nOral \nmagnesium\nPlacebo/no \ntreatment\nRelative\n(95% CI)\nAbsolute\nNo leg cramps after treatment\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n11/34 \n(32.4%)\n2/35 \n(5.7%)\nRR 5.66 \n(1.35 to 23.68)\n266 more per 1000 \n(from 20 more to 1000 more)\nLOW\n50% reduction in number of leg cramps\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nn",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.3a) from the Cochrane review by Zhou et al. (2015) comparing oral magnesium supplementation against placebo or no treatment for leg cramps in pregnancy. Summarizes GRADE evidence from single-trial analyses showing a higher proportion of women achieving a >= 50% reduction in the number of leg cramps (86 women; RR 1.42, 95% CI 1.09–1.86; 254 more per 1000; high certainty) and no leg cramps after treatment in one trial (69 women; RR 5.66, 95% CI 1.35–23.68; 266 more per 1000; low certainty), alongside uncertain effects in a second trial on partial improvement (42 women; RR 1.07, 95% CI 0.71–1.61; very low certainty) or complete recovery (42 women; RR 3.00, 95% CI 0.68–13.20; very low certainty) and imprecise low-certainty estimates for nausea (86 women; RR 1.83, 95% CI 0.75–4.51), diarrhoea (86 women; RR 6.00, 95% CI 0.75–47.76), and any gastrointestinal side-effects (45 women; RR 0.96, 95% CI 0.36–2.52).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-084",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.3b: Oral calcium versus no treatment",
      "pageStart": 101,
      "pageEnd": 102,
      "target": "../sections/sec-084-eb-table-d3b-oral-calcium-versus-no-treatment.md",
      "narrative": null,
      "content": "EB Table D.3b: Oral calcium versus no treatment\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nOral calcium \nNo treatment\nRelative\n(95% CI)\nAbsolute\nNo leg cramps after treatment\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n9/22 \n(40.9%)\n1/21 \n(4.8%)\nRR 8.59 \n(1.19 to 62.07)\n361 more per 1000 \n(from 9 more to 1000 more)\nLOW\nComposite outcome: symptoms of leg cramps (intensity and frequency) – partial improvement: decrease in intensity and frequenc",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.3b) from the Cochrane review by Zhou et al. (2015) comparing oral calcium supplementation against no treatment for leg cramps in pregnancy (1 RCT). Reports GRADE evidence showing higher rates of no leg cramps after treatment (43 women; RR 8.59, 95% CI 1.19–62.07; 361 more per 1000; low certainty) and complete recovery on a composite intensity/frequency outcome (42 women; RR 5.50, 95% CI 1.38–21.86; 429 more per 1000; low certainty), alongside a very low-certainty, imprecise estimate for partial symptom improvement (42 women; RR 0.64, 95% CI 0.36–1.15; 240 fewer per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-085",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.3c: Vitamin B1 and B6 versus no treatment",
      "pageStart": 102,
      "pageEnd": 102,
      "target": "../sections/sec-085-eb-table-d3c-vitamin-b1-and-b6-versus-no-treatme.md",
      "narrative": null,
      "content": "EB Table D.3c: Vitamin B1 and B6 versus no treatment\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nOral vitamin B1 \nand B6\nNo treatment\nRelative\n(95% CI)\nAbsolute\nPartial improvement: decrease in intensity and frequency\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n4/21 \n(19%)\n14/21 \n(66.7%)\nRR 0.29 \n(0.11 to 0.73)\n473 fewer per 1000 \n(from 180 fewer to 593 fewer)\nLOW\nComplete recovery: no leg cramps after treatment\n1\nrandomized \ntrials\nserious1\nn",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.3c) from Zhou et al. (2015) comparing combined oral vitamin B1 and B6 supplementation against no treatment for leg cramps in pregnancy (1 RCT, 42 women). Reports low-certainty GRADE evidence (downgraded for risk of bias, small sample size, and few events) showing a higher rate of complete recovery with no leg cramps after treatment (RR 7.50, 95% CI 1.95–28.81; 619 more per 1000) and correspondingly fewer women experiencing only partial improvement in cramp intensity and frequency (RR 0.29, 95% CI 0.11–0.73; 473 fewer per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-086",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.3d: Oral calcium versus oral vitamin C",
      "pageStart": 102,
      "pageEnd": 103,
      "target": "../sections/sec-086-eb-table-d3d-oral-calcium-versus-oral-vitamin-c.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nOral calcium\nOral vitamin C\nRelative\n(95% CI)\nAbsolute\nNo leg cramps after treatment\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2,3\nnone\n8/30 \n(26.7%)\n6/30 \n(20%)\nRR 1.33 \n(0.53 to 3.38)\n66 more per 1000 \n(from 94 fewer to 476 more)\nLOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (i.e. < 40%) from studies “C”. \n2.\t Small sample size and few events. \n3.\t\nWid",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.3d) from Zhou et al. (2015) comparing oral calcium against oral vitamin C for leg cramps in pregnancy (1 RCT, 60 women). Reports low-certainty GRADE evidence (downgraded for risk of bias, small sample size, few events, and a wide confidence interval) showing no clear difference in the proportion of women with no leg cramps after treatment (RR 1.33, 95% CI 0.53–3.38; 66 more per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-087",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Interventions for low back and pelvic pain",
      "pageStart": 103,
      "pageEnd": 103,
      "target": "../sections/sec-087-d4-interventions-for-low-back-and-pelvic-pain.md",
      "narrative": null,
      "content": "D.4. Interventions for low back and pelvic pain\nSource: Liddle SD, Pennick V. Interventions for preventing and treating low-back and pelvic pain during pregnancy. Cochrane Database Syst Rev. 2015;(9):CD001139.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading and source citation for Section D.4 (Interventions for low back and pelvic pain), citing the Cochrane review by Liddle and Pennick (2015) on interventions for preventing and treating low-back and pelvic pain during pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-088",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.4a: Any exercise plus usual antenatal care (ANC) versus usual ANC",
      "pageStart": 103,
      "pageEnd": 104,
      "target": "../sections/sec-088-eb-table-d4a-any-exercise-plus-usual-antenatal-c.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAny exercise + \nusual ANC \nUsual ANC \nRelative\n(95% CI)\nAbsolute\nLow back pain intensity (better indicated by lower values)\n7\nrandomized \ntrials\nvery serious1\nserious2\nno serious \nindirectness\nno serious \nimprecision\nnone\n321\n324\nSMD 0.64 lower \n(1.03 to 0.25 lower)\n-\n \nVERY LOW\nFunctional disability (better indicated by lower values)\n2\nrandomized \ntrials\nserious3\nno serious \ninconsistency\nno serious \nindirectness\nserious4\nnone\n74\n72\nSMD 0.56 lower",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.4a) from the Cochrane review by Liddle and Pennick (2015) comparing any exercise intervention plus usual antenatal care (ANC) against usual ANC alone for low back and pelvic pain during pregnancy. Summarizes GRADE evidence showing reductions in low back pain intensity (7 RCTs, 645 women; SMD 0.64 lower, 95% CI 1.03–0.25 lower; very low certainty), functional disability (2 RCTs, 146 women; SMD 0.56 lower, 95% CI 0.89–0.23 lower; low certainty), and the proportion of women reporting pain on a visual analogue scale (4 RCTs, 1176 women; RR 0.66, 95% CI 0.45–0.97; 241 fewer per 1000; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-089",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.4b: Bellybra versus Tubigrip support belts",
      "pageStart": 104,
      "pageEnd": 104,
      "target": "../sections/sec-089-eb-table-d4b-bellybra-versus-tubigrip-support-be.md",
      "narrative": null,
      "content": "EB Table D.4b: Bellybra versus Tubigrip support belts\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nBellybra \nTubigrip\nRelative\n(95% CI)\nAbsolute\nLow-back pain – measured with visual analogue scale (VAS) (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2,3\nnone\n46\n48\nMD 0.2 lower \n(1.19 lower to 0.79 higher)\n-\n \nVERY LOW\nFunctional disability – (MD; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno ser",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.4b) from Liddle and Pennick (2015) comparing Bellybra versus Tubigrip maternity support belts for low back pain in pregnancy (1 RCT, 94 women). Reports very low-certainty GRADE evidence (downgraded for risk of bias, small sample size, and wide confidence intervals) showing no clear difference in visual analogue scale (VAS) low-back pain (MD 0.20 lower, 95% CI 1.19 lower to 0.79 higher) or functional disability (MD 0.90 lower, 95% CI 1.81 lower to 0.01 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-090",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.4c: Acupuncture plus usual ANC versus usual ANC",
      "pageStart": 104,
      "pageEnd": 105,
      "target": "../sections/sec-090-eb-table-d4c-acupuncture-plus-usual-anc-versus-u.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAcupuncture + \nusual ANC\nUsual ANC\nRelative\n(95% CI)\nAbsolute\nDecreased low back and pelvic pain\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n22/37 \n(59.5%)\n5/35 \n(14.3%)\nRR 4.16 \n(1.77 to 9.78)\n451 more per 1000 \n(from 110 more to 1000 more)\nLOW\n1.\t\nNo explanation was provided. \n2.\t Small sample size and few events.\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy exper",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.4c) from Liddle and Pennick (2015) comparing acupuncture plus usual antenatal care (ANC) against usual ANC alone for low back and pelvic pain in pregnancy (1 RCT, 72 women). Reports low-certainty GRADE evidence showing a higher proportion of women with decreased low back and pelvic pain in the acupuncture group (RR 4.16, 95% CI 1.77–9.78; 451 more per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-091",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.4d: Acupuncture plus usual ANC versus individualized physiotherapy plus usual ANC",
      "pageStart": 105,
      "pageEnd": 105,
      "target": "../sections/sec-091-eb-table-d4d-acupuncture-plus-usual-anc-versus-i.md",
      "narrative": null,
      "content": "EB Table D.4d: Acupuncture plus usual ANC versus individualized physiotherapy plus usual ANC\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAcupuncture + \nusual ANC \nIndividualized \nphysiotherapy + \nusual ANC\nRelative\n(95% CI)\nAbsolute\nWomen rating treatment as good or excellent\n1\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n27/28 \n(96.4%) \n14/18 \n(77.8%)\nRR 1.24 \n(0.96 to 1.6)\n187 more per 1000 \n(from 31 fewer to 467 more)\n \nVERY LOW\n1.\t\nMost",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.4d) from Liddle and Pennick (2015) comparing acupuncture plus usual antenatal care (ANC) against individualized physiotherapy plus usual ANC for low back and pelvic pain in pregnancy (1 RCT, 46 women). Reports very low-certainty GRADE evidence showing an imprecise difference in the proportion of women rating their treatment as good or excellent (RR 1.24, 95% CI 0.96–1.60; 187 more per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-092",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.4e: Multimodal intervention (manual therapy/chiropractic, exercise at home and education) versus usual care (rest, exercise, heat pads and analgesics)",
      "pageStart": 105,
      "pageEnd": 106,
      "target": "../sections/sec-092-eb-table-d4e-multimodal-intervention-manual-ther.md",
      "narrative": null,
      "content": "(rest, exercise, heat pads and analgesics)\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nBellybra \nTubigrip\nRelative\n(95% CI)\nAbsolute\nPain (MD; better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nserious1\n87\n82\nMD 2.7 lower \n(3.54 to 1.86 lower)\n-\nMODERATE\nFunctional disability (MD; better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno ser",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.4e) from Liddle and Pennick (2015) comparing a multimodal intervention (manual therapy/chiropractic care, home exercise, and education) against usual care (rest, exercise, heat pads, and analgesics) for low back and pelvic pain in pregnancy (1 RCT, 169 women; source table column headers mislabelled as Bellybra/Tubigrip). Reports moderate-certainty GRADE evidence (downgraded for small sample size) of lower pain scores (MD 2.70 lower, 95% CI 3.54–1.86 lower) and lower functional disability scores (MD 1.40 lower, 95% CI 2.09–0.71 lower) with the multimodal intervention.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-093",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Interventions for constipation",
      "pageStart": 106,
      "pageEnd": 106,
      "target": "../sections/sec-093-d5-interventions-for-constipation.md",
      "narrative": null,
      "content": "D.5. Interventions for constipation\nSource: Rungsiprakarn P, Laopaiboon M, Sangkomkamhang US, Lumbiganon P, Pratt JJ. Interventions for treating constipation in pregnancy. Cochrane Database Syst Rev. 2015;(9):CD011448.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading and source citation for Section D.5 (Interventions for constipation), citing the Cochrane review by Rungsiprakarn et al. (2015) on interventions for treating constipation in pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-094",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.5a: Fibre supplementation versus no intervention",
      "pageStart": 106,
      "pageEnd": 107,
      "target": "../sections/sec-094-eb-table-d5a-fibre-supplementation-versus-no-int.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nAny exercise + \nusual ANC \nUsual ANC \nRelative\n(95% CI)\nAbsolute\nFrequency of stools (per week) (better indicated by higher values)\n1\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n27\n13\nMD 2.24 higher \n(0.96 to 3.52 higher)\n-\n \nVERY LOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” with a substantial proportion (> 40%) from studies “C”. \n2.\t Wide CI crossing the line of no effect”.\nWe",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.5a) from the Cochrane review by Rungsiprakarn et al. (2015) comparing dietary fibre supplementation against no intervention for constipation in pregnancy (1 RCT, 40 women; source table column headers mislabelled as Any exercise + usual ANC / Usual ANC). Reports very low-certainty GRADE evidence of increased weekly stool frequency with fibre supplementation (MD 2.24 higher per week, 95% CI 0.96–3.52 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-095",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.5b: Stimulant laxatives versus bulk-forming laxatives",
      "pageStart": 107,
      "pageEnd": 108,
      "target": "../sections/sec-095-eb-table-d5b-stimulant-laxatives-versus-bulk-for.md",
      "narrative": null,
      "content": "EB Table D.5b: Stimulant laxatives versus bulk-forming laxatives\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nStimulant \nlaxatives \nBulk-forming \nlaxatives\nRelative\n(95% CI)\nAbsolute\nImprovement in constipation\n1\nrandomized \ntrials\nvery serious1\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n54/70 \n(77.1%)\n34/70 \n(48.6%)\nRR 1.59 \n(1.21 to 2.09)\n287 more per 1000 \n(from 102 more to 529 more)\nLOW\nAbdominal discomfort\n1\nrandomized \ntrials\nvery serious1\nno serious",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.5b) from Rungsiprakarn et al. (2015) comparing stimulant laxatives against bulk-forming laxatives for constipation in pregnancy (1 RCT, 140 women). Reports GRADE evidence showing greater improvement in constipation (RR 1.59, 95% CI 1.21–2.09; 287 more per 1000; low certainty) but higher rates of abdominal discomfort (RR 2.33, 95% CI 1.15–4.73; 171 more per 1000; low certainty) and diarrhoea (RR 4.50, 95% CI 1.01–20.09; 100 more per 1000; very low certainty) with stimulant laxatives, and no clear difference in women's satisfaction (RR 1.06, 95% CI 0.77–1.46; very low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-096",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Interventions for varicose veins and oedema",
      "pageStart": 108,
      "pageEnd": 108,
      "target": "../sections/sec-096-d6-interventions-for-varicose-veins-and-oedema.md",
      "narrative": null,
      "content": "D.6. Interventions for varicose veins and oedema\nSource: Smyth RMD, Aflaifel N, Bamigboye AA. Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database Syst Rev. 2015;(10):CD001066.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading and source citation for Section D.6 (Interventions for varicose veins and oedema), citing the Cochrane review by Smyth, Aflaifel, and Bamigboye (2015) on interventions for varicose veins and leg oedema in pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-097",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.6a: Rutoside versus placebo",
      "pageStart": 108,
      "pageEnd": 109,
      "target": "../sections/sec-097-eb-table-d6a-rutoside-versus-placebo.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nRutoside \nPlacebo\nRelative\n(95% CI)\nAbsolute\nRelief of symptoms associated with varicose veins\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n24/37 \n(64.9%)\n11/32 \n(34.4%)\nRR 1.89 \n(1.11 to 3.22)\n306 more per 1000 \n(from 38 more to 763 more)\nLOW\nSide-effects\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nvery serious2,3\nnone\n3/37 \n(8.1%)\n2/32 \n(6.3%)\nRR 1.3 \n(0.23 to 7.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.6a) from the Cochrane review by Smyth, Aflaifel, and Bamigboye (2015) comparing oral rutoside against placebo for varicose veins in pregnancy (1 RCT, 69 women). Reports GRADE evidence showing greater relief of varicose-vein symptoms with rutoside (RR 1.89, 95% CI 1.11–3.22; 306 more per 1000; low certainty), alongside very low-certainty, imprecise estimates for maternal side-effects (RR 1.30, 95% CI 0.23–7.28; 19 more per 1000) and deep vein thrombosis complications (RR 0.17, 95% CI 0.01–3.49; 52 fewer per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-098",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.6b: External pneumatic intermittent compression versus rest",
      "pageStart": 109,
      "pageEnd": 109,
      "target": "../sections/sec-098-eb-table-d6b-external-pneumatic-intermittent-com.md",
      "narrative": null,
      "content": "EB Table D.6b: External pneumatic intermittent compression versus rest\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nExternal \npneumatic \nintermittent \ncompression \nRest\nRelative\n(95% CI)\nAbsolute\nSymptoms associated with oedema (change in lower leg volume, unit of analysis not stated) (MD; better indicated by lower values)\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nserious1\nnone\n17\n18\nMD 258.8 lower \n(566.91 lower to 49.31 higher)\n-\nLOW\n1.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.6b) from Smyth, Aflaifel, and Bamigboye (2015) comparing external pneumatic intermittent compression against rest for leg oedema in pregnancy (1 RCT, 35 women). Reports low-certainty GRADE evidence (downgraded for a wide confidence interval crossing no effect) on change in lower leg volume (MD 258.8 lower, 95% CI 566.91 lower to 49.31 higher; unit of analysis not stated).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-099",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.6c: Reflexology versus rest",
      "pageStart": 109,
      "pageEnd": 110,
      "target": "../sections/sec-099-eb-table-d6c-reflexology-versus-rest.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nReflexology\nRest\nRelative\n(95% CI)\nAbsolute\nWoman's satisfaction \n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nvery serious2,3\nnone\n27/45 \n(60%)\n1/10 \n(10%)\nRR 6 \n(0.92 to 39.11)\n500 more per 1000 \n(from 8 fewer to 1000 more)\n \nVERY LOW\nSymptoms associated with oedema\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n30/33 \n(90.9%)\n1/10 \n(10%)\nRR 9.09 \n(1.41 to 58.54)\n80",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.6c) from Smyth, Aflaifel, and Bamigboye (2015) comparing foot reflexology against rest for leg oedema in pregnancy (1 RCT). Reports GRADE evidence showing reduced symptoms associated with oedema (43 women; RR 9.09, 95% CI 1.41–58.54; 809 more per 1000; low certainty) and a very low-certainty, imprecise estimate for women's satisfaction (55 women; RR 6.00, 95% CI 0.92–39.11; 500 more per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-100",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.6d: Water immersion versus leg elevation",
      "pageStart": 110,
      "pageEnd": 110,
      "target": "../sections/sec-100-eb-table-d6d-water-immersion-versus-leg-elevatio.md",
      "narrative": null,
      "content": "EB Table D.6d: Water immersion versus leg elevation\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nWater \nimmersion\nLeg elevation\nRelative\n(95% CI)\nAbsolute\nWomen with reduction in leg volume (oedema)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n6/16 \n(37.5%)\n14/16 \n(87.5%)\nRR 0.43 \n(0.22 to 0.83)\n499 fewer per 1000 \n(from 149 fewer to 683 fewer)\nLOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (< 4",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.6d) from Smyth, Aflaifel, and Bamigboye (2015) comparing water immersion against leg elevation for leg oedema in pregnancy (1 RCT, 32 women). Reports low-certainty GRADE evidence (downgraded for risk of bias, small sample size, and few events) showing a smaller proportion of women with reduced leg volume in the water-immersion group as tabulated (6/16 vs 14/16; RR 0.43, 95% CI 0.22–0.83; 499 fewer per 1000).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-101",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table D.6e: Foot massage versus “routine care”",
      "pageStart": 110,
      "pageEnd": 111,
      "target": "../sections/sec-101-eb-table-d6e-foot-massage-versus-routine-care.md",
      "narrative": null,
      "content": "Quality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nFoot massage \nRoutine care\nRelative\n(95% CI)\nAbsolute\nSymptoms associated with oedema (lower leg circumference in centimetres; better indicated by lower values)\n1\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nserious2\nnone\n40\n40\nMD 0.11 lower \n(1.02 lower to 0.8 higher)\n-\nLOW\n1.\t\nMost of the pooled effect provided by studies “B” or “C” without a substantial proportion (< 40%) from studies “C”. \n2.\t Wide CI crossing th",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table D.6e) from Smyth, Aflaifel, and Bamigboye (2015) comparing foot massage against routine care for leg oedema in pregnancy (1 RCT, 80 women). Reports low-certainty GRADE evidence showing no clear difference in lower leg circumference in centimetres (MD 0.11 cm lower, 95% CI 1.02 lower to 0.80 higher).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-102",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Health systems interventions to improve antenatal care utilization and quality",
      "pageStart": 111,
      "pageEnd": 111,
      "target": "../sections/sec-102-e-health-systems-interventions-to-improve-antena.md",
      "narrative": null,
      "content": "E. Health systems interventions to improve antenatal care utilization and quality",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing Part E (Health systems interventions to improve antenatal care utilization and quality) of the WHO antenatal care guideline evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-103",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Woman-held case notes",
      "pageStart": 111,
      "pageEnd": 111,
      "target": "../sections/sec-103-e1-woman-held-case-notes.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-104",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table E.1: Woman-held case notes versus control",
      "pageStart": 111,
      "pageEnd": 112,
      "target": "../sections/sec-104-eb-table-e1-woman-held-case-notes-versus-control.md",
      "narrative": null,
      "content": "Source: Brown HC, Smith HJ, Mori R, Noma H. Giving women their own case notes to carry during pregnancy. Cochrane Database Syst Rev. 2015;(10):CD002856.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nWomen carrying \ntheir own case \nnotes \nControl \n(facility-held \ncase notes)\nRelative\n(95% CI)\nAbsolute\nWomen who felt in control\n2\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n87/229 \n(38%)\n52/221 \n(23.5%)\nRR 1.56 \n(1.18 to 2.06)\n132 more",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table E.1) from the Cochrane review by Brown et al. (2015) comparing woman-held case notes during pregnancy against facility-held control notes. Summarizes GRADE evidence showing that women carrying their own case notes were more likely to feel in control of their care (2 RCTs, 450 women; RR 1.56, 95% CI 1.18–2.06; 132 more per 1000; moderate certainty), with no clear difference in overall satisfaction with antenatal care (2 RCTs, 698 women; RR 1.02, 95% CI 0.92–1.29; low certainty), notes lost or left at home (2 RCTs, 347 women; RR 0.38, 95% CI 0.04–3.84; very low certainty), or stillbirth and neonatal death (2 RCTs, 713 women; RR 0.77, 95% CI 0.17–3.48; low certainty), alongside a very low-certainty estimate of increased caesarean section in one cluster-randomized trial (501 women; RR 1.51, 95% CI 1.10–2.08).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-105",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Midwife-led continuity of care (MLCC)",
      "pageStart": 112,
      "pageEnd": 112,
      "target": "../sections/sec-105-e2-midwife-led-continuity-of-care-mlcc.md",
      "narrative": null,
      "content": "E.2. Midwife-led continuity of care (MLCC)",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section E.2 (Midwife-led continuity of care [MLCC]) in Part E of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-106",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table E.2: MLCC versus other models",
      "pageStart": 112,
      "pageEnd": 113,
      "target": "../sections/sec-106-eb-table-e2-mlcc-versus-other-models.md",
      "narrative": null,
      "content": "Source: Sandall J, Soltani H, Gates S, Shennan A, Devane D. Midwife-led continuity models versus other models of care for childbearing women. Cochrane Database Syst Rev. 2015;(9):CD004667.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nMLCC\nOther models\nRelative\n(95% CI)\nAbsolute\nCaesarean birth\n14\nrandomized \ntrials\nserious1\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nreporting \nbias2\n1281/9667 \n(13.3%)\n1242/8007 \n(15.5%)\nRR 0.92 \n(0.84 to 1)\n12 fewer per 1000 \n(fr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table E.2) from the Cochrane review by Sandall et al. (2015) comparing midwife-led continuity of care (MLCC) models against other models of care for childbearing women. Presents GRADE evidence showing that MLCC increased spontaneous vaginal birth (12 RCTs, 16 687 women; RR 1.05, 95% CI 1.03–1.07; 33 more per 1000; moderate certainty) and maternal satisfaction with antenatal care (4 RCTs, 5419 women; RR 1.31, 95% CI 1.11–1.54; 157 more per 1000; low certainty), while reducing preterm birth < 37 weeks (8 RCTs, 13 238 women; RR 0.76, 95% CI 0.64–0.91; 15 fewer per 1000; moderate certainty), overall fetal loss and neonatal death (13 RCTs, 17 561 births; RR 0.84, 95% CI 0.71–0.99; 5 fewer per 1000; moderate certainty), instrumental vaginal birth (13 RCTs, 17 501 women; RR 0.90, 95% CI 0.83–0.97; 14 fewer per 1000; low certainty), and possibly caesarean birth (14 RCTs, 17 674 women; RR 0.92, 95% CI 0.84–1.00; 12 fewer per 1000; low certainty), with no clear difference in low birth weight < 2500 g (7 RCTs, 11 458 births; RR 0.96, 95% CI 0.82–1.13; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-107",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Figure E.2: Additional analysis: MLCC model versus other models of care: satisfaction",
      "pageStart": 113,
      "pageEnd": 114,
      "target": "../sections/sec-107-figure-e2-additional-analysis-mlcc-model-versus.md",
      "narrative": null,
      "content": "Figure E.2: Additional analysis: MLCC model versus other models of care: satisfaction\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Figure caption for Figure E.2 presenting an additional forest-plot analysis comparing maternal satisfaction between midwife-led continuity of care (MLCC) models and other models of care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-108",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Group antenatal care (ANC)",
      "pageStart": 114,
      "pageEnd": 114,
      "target": "../sections/sec-108-e3-group-antenatal-care-anc.md",
      "narrative": null,
      "content": "E.3. Group antenatal care (ANC)",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section E.3 (Group antenatal care [ANC]) in Part E of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-109",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table E.3: Group ANC versus individual ANC",
      "pageStart": 114,
      "pageEnd": 116,
      "target": "../sections/sec-109-eb-table-e3-group-anc-versus-individual-anc.md",
      "narrative": null,
      "content": "Source: Catling CJ, Medley N, Foureur M, Ryan C, Leap N, Teate A, Homer CSE. Group versus conventional antenatal care for women. Cochrane Database Syst Rev. 2015;(2):CD007622.\nQuality assessment\nNo. of women\nEffect\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nGroup ANC\nIndividual \nantenatal care \n(adjusted data)\nRelative\n(95% CI)\nAbsolute\nSpontaneous vaginal birth\n1\nrandomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nserious1\nno serious \nimprecision\nnone\n94/162 \n(58%)\n97/160 \n(60.6%)\nRR 0.96 \n(0.8 to 1.15)\n24 fewer",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table E.3) from the Cochrane review by Catling et al. (2015) comparing group antenatal care (ANC) against conventional individual ANC. Summarizes GRADE evidence showing higher maternal satisfaction with group ANC in one US CenteringPregnancy trial (993 women; MD 4.90 higher, 95% CI 3.10–6.70 higher; low certainty) and a borderline reduction in preterm birth (3 RCTs, 1888 women; RR 0.75, 95% CI 0.57–1.00; 26 fewer per 1000; moderate certainty), with no clear difference in spontaneous vaginal birth (1 RCT, 322 women; RR 0.96, 95% CI 0.80–1.15; moderate certainty), caesarean section (2 RCTs, 842 women; RR 0.83, 95% CI 0.68–1.02; very low certainty), small-for-gestational-age infants (2 RCTs, 1473 births; RR 0.92, 95% CI 0.68–1.24; very low certainty), low birth weight (3 RCTs, 1935 births; RR 0.92, 95% CI 0.68–1.23; moderate certainty), or perinatal mortality (3 RCTs, 1943 births; RR 0.63, 95% CI 0.32–1.25; low certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-110",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Community-based interventions to improve communication and support",
      "pageStart": 116,
      "pageEnd": 116,
      "target": "../sections/sec-110-e4-community-based-interventions-to-improve-comm.md",
      "narrative": null,
      "content": "E.4. Community-based interventions to improve communication and support",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section E.4 (Community-based interventions to improve communication and support) in Part E of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-111",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table E.4: Community-based interventions (women’s groups, home visits or intervention packages with home visits and community mobilization) versus control",
      "pageStart": 116,
      "pageEnd": 119,
      "target": "../sections/sec-111-eb-table-e4-community-based-interventions-womens.md",
      "narrative": null,
      "content": "community mobilization) versus control\nSource: Mbuagbaw L, Medley N, Darzi AJ, Richardson M, Habiba Garga K, Ongolo-Zogo P. Health system and community level interventions for improving antenatal care coverage and health outcomes. Cochrane Database \nSyst Rev. 2015;(12):CD010994.\nQuality assessment\nNo. of women1\nEffect2\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nCommunity-based \ninterventions \nControl\nRelative\n(95% CI)\nANC coverage: four or more visits – women’s groups\n3\nrandomized \ntrials\nserious3\nno serious \ninconsistency\nno seri",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table E.4) from the Cochrane review by Mbuagbaw et al. (2015) comparing community-based interventions (participatory women's groups, home visits, or combined home-visit and community-mobilization packages) against control across cluster-randomized trials. Presents GRADE evidence showing increases in ANC coverage of at least one visit with women's groups (3 RCTs, 66 089 women; RR 1.77, 95% CI 1.21–2.58; moderate certainty) and with combined home visits plus community mobilization (4 RCTs, 143 098 women; RR 1.76, 95% CI 1.43–2.16; high certainty), as well as reduced perinatal mortality with combined packages (3 RCTs, 29 282 births; RR 0.65, 95% CI 0.48–0.88; moderate certainty), alongside non-significant or borderline effects across subgroups on ANC coverage of four or more visits (women's groups: RR 1.05, low certainty; home visits: RR 1.09, high certainty; combined packages: RR 1.51, moderate certainty), health-facility deliveries (women's groups: RR 1.04, low certainty; home visits: RR 1.08, moderate certainty; combined packages: RR 1.46, moderate certainty), maternal mortality (women's groups: 7 RCTs, 116 805 women, RR 0.78, 95% CI 0.60–1.03, low certainty; combined packages: 2 RCTs, RR 0.76, moderate certainty), perinatal mortality with women's groups (6 RCTs, RR 0.91, low certainty) or home visits (4 RCTs, RR 0.91, high certainty), and low birth weight (RR 0.78, moderate certainty) or preterm birth (RR 0.88, moderate certainty) with home visits.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-112",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antenatal care contact schedules",
      "pageStart": 119,
      "pageEnd": 119,
      "target": "../sections/sec-112-e7-antenatal-care-contact-schedules.md",
      "narrative": null,
      "content": "E.7. Antenatal care contact schedules",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section E.7 (Antenatal care contact schedules) in Part E of the evidence base web supplement.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-113",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "EB Table E.7: Focused ANC (FANC) model (minimum of four visits) versus standard ANC model (minimum of eight visits)",
      "pageStart": 119,
      "pageEnd": 121,
      "target": "../sections/sec-113-eb-table-e7-focused-anc-fanc-model-minimum-of-fo.md",
      "narrative": null,
      "content": "Source: Dowswell T, Carroli G, Duley L, Gates S, Gülmezoglu AM, Khan-Neelofur D, Piaggio G. Alternative versus standard packages of antenatal care for low-risk pregnancy. Cochrane Database Syst Rev. \n2015;(7):CD000934.\nQuality assessment\nNo. of women1\nEffect2\nCertainty\nNo. of \nstudies\nDesign\nRisk of bias\nInconsistency\nIndirectness\nImprecision\nOther \nconsiderations\nFANC model\nStandard ANC \nmodel\nRelative\n(95% CI)\nCaesarean section\n1\ncluster-randomized \ntrials\nno serious risk \nof bias\nno serious \ninconsistency\nno serious \nindirectness\nno serious \nimprecision\nnone\n11 624\n11 121\nRR 1 \n(0.89 to 1.1",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Evidence base table (EB Table E.7) from the Cochrane review by Dowswell et al. (2015) comparing the focused antenatal care (FANC) model (minimum of four visits) against the standard ANC model (minimum of eight visits) across cluster-randomized trials. Summarizes GRADE evidence showing increased perinatal mortality with the reduced-visit FANC model (3 cluster RCTs, 51 323 births; RR 1.15, 95% CI 1.01–1.32; moderate certainty), with little or no difference between models in caesarean section (1 cluster RCT, 22 745 women; RR 1.00, 95% CI 0.89–1.11; high certainty), maternal death (3 cluster RCTs, 51 504 women; RR 1.13, 95% CI 0.50–2.57; low certainty), pre-eclampsia (3 cluster RCTs, 48 853 women; RR 0.94, 95% CI 0.73–1.22; very low certainty), low birth weight (3 cluster RCTs, 46 220 births; RR 1.04, 95% CI 0.97–1.12; moderate certainty), small-for-gestational-age infants (2 cluster RCTs, 37 951 births; RR 1.01, 95% CI 0.90–1.14; low certainty), or preterm birth (3 cluster RCTs, 48 094 births; RR 0.99, 95% CI 0.91–1.08; moderate certainty).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-114",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search strategies for the evidence base",
      "pageStart": 121,
      "pageEnd": 121,
      "target": "../sections/sec-114-search-strategies-for-the-evidence-base.md",
      "narrative": null,
      "content": "Search strategies for the evidence base",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Section heading introducing the final part of the web supplement detailing the search strategies used to assemble the guideline evidence base.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-115",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search strategy to identify existing ANC guidelines",
      "pageStart": 121,
      "pageEnd": 121,
      "target": "../sections/sec-115-1-search-strategy-to-identify-existing-anc-guide.md",
      "narrative": null,
      "content": "In December 2013, a systematic search was conducted for evidence-based guidelines in the following databases: \nPubMed,5 LILACS6 (an index of scientific and technical literature of Latin America and the Caribbean) and Trip7 \n(Turning Research into Practice), and in the guidelines repository maintained by the Geneva Foundation for Medical \nEducation and Research (GFMER). To identify as many relevant guidelines as possible, a broad search strategy \nwas chosen. In PubMed, the words “pregnancy or prenatal or antenatal”, and “care or management or screening” \nwere used, selecting guideline/practice",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the December 2013 systematic search strategy used to identify existing evidence-based clinical practice guidelines on antenatal care published after January 2000 across PubMed, LILACS, the Trip Database, the Geneva Foundation for Medical Education and Research (GFMER) guidelines repository, and reference lists, detailing the database-specific search terms and filters.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-116",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search results",
      "pageStart": 121,
      "pageEnd": 122,
      "target": "../sections/sec-116-search-results.md",
      "narrative": null,
      "content": "4\t Abalos A, Chamillard M, Diaz V, Tunçalp Ö, Gülmezoglu AM. Antenatal care for healthy pregnant women: a mapping of interventions \nfrom existing guidelines to inform the development of new WHO guidance on antenatal care. BJOG. 2016;123(4):519–28. doi:10.1111/1471-\n0528.13820.\n5\t Available at: https://www.ncbi.nlm.nih.gov/pubmed/ \n6\t Available at: http://lilacs.bvsalud.org/en/ \n7\t Available at: https://www.tripdatabase.com/ \nPubMed\nn=990\nTrip Database\nn=844\nLILACS\nn=38\nGFMER\nn=14\nPubMed\nn=990\nPotentially eligible\nn=133\nEligible guidelines\nn=79\nExcluded from titles & abstracts\nn=1753\nDuplicates",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the search results and screening flow diagram (citing Abalos et al., 2016) for existing antenatal care guidelines across PubMed (n = 990), Trip Database (n = 844), LILACS (n = 38), and GFMER (n = 14), narrowing 1886 initial records and 6 additional records from reference checking and expert identification to 133 potentially eligible papers and 85 selected guidelines (15 general ANC guidelines and 70 condition-specific guidelines).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-117",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search strategy for qualitative meta-synthesis of women’s views",
      "pageStart": 122,
      "pageEnd": 122,
      "target": "../sections/sec-117-2-search-strategy-for-qualitative-meta-synthesis.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-118",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Inclusion criteria",
      "pageStart": 122,
      "pageEnd": 122,
      "target": "../sections/sec-118-inclusion-criteria.md",
      "narrative": null,
      "content": "i. Study design\nn\nn Studies using qualitative designs, including ethnography, phenomenology, case studies, grounded theory and \nmixed methods. \nn\nn Studies using interviews, focus group discussions, open-ended survey questions, diaries and other narrative-\nbased data collection methods. \nii. Study topic/focus\nn\nn Studies focused on, or with substantial sections focused on, views, attitudes, experiences, facilitators and/or \nbarriers related to routine ANC (studies that only reported on these aspects of care in the context of services \nthat are provided for women/fetuses with particular health",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Specifies the five inclusion criteria (study design, study topic/focus on routine ANC, population of pregnant or postnatal women since 1998, publication date range of January 2000 to August 2014 following the introduction of FANC, and no language restrictions) for the qualitative evidence synthesis of pregnant women's views and experiences of routine antenatal care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-119",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search terms",
      "pageStart": 122,
      "pageEnd": 124,
      "target": "../sections/sec-119-search-terms.md",
      "narrative": null,
      "content": "Participants\nArea of Interest\nContext\nPhenomenon of interest\nStudy design\nwoman OR women* OR \npatient* OR consumer* \nOR service user*]\nAntenatal* or prenatal* or \nantepartum or perinatal \nor pregnan* \ncare OR support* OR \nhealth* OR clinic* or \noutpatient* OR session* \nOR matern* OR service* \nOR office or education* \nwant* OR like OR desire* \nOR require* OR expect* \nOR anticipat* OR view* OR \nexperience* OR perspective* \nOR perception* OR opinion* \nOR assum* OR know* OR \nunderstand* OR encounter* \nOR belief* OR believe* \nOR attitude* OR help* OR \npromot* OR enable* OR \nempower* OR permi* OR \ne",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Details the five-column search term matrix (Participants, Area of Interest, Context, Phenomenon of interest, and Study design), dual-reviewer screening and citation-chaining procedures, and the seven databases searched (AJOL, AMED, CINAHL, Embase, Latindex, MEDLINE, and PsycINFO, plus Zetoc alerts across > 50 journals) for the Cochrane qualitative evidence synthesis on factors influencing pregnant women's uptake of routine antenatal services (Downe et al., 2016, CD012392).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-120",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search strategy for qualitative meta-synthesis of health-care providers’ views",
      "pageStart": 124,
      "pageEnd": 124,
      "target": "../sections/sec-120-3-search-strategy-for-qualitative-meta-synthesis.md",
      "narrative": null,
      "content": "providers’ views16",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Subsection heading introducing Section 3 of the search strategies, covering the qualitative meta-synthesis of health-care providers' views on routine antenatal care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-121",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Inclusion criteria",
      "pageStart": 124,
      "pageEnd": 125,
      "target": "../sections/sec-121-inclusion-criteria.md",
      "narrative": null,
      "content": "i. Study design\nn\nn Studies using qualitative designs, including ethnography, phenomenology, case studies, grounded theory and \nmixed methods. \nn\nn Studies using interviews, focus group discussions, open-ended survey questions, diaries and other narrative-\nbased data collection methods. \nii. Study topic/focus\nn\nn Studies focused on, or with substantial sections focused on, views, attitudes, experiences, facilitators and/or \nbarriers related to routine antenatal care (studies that only reported on these aspects of care in the context of \nservices that are provided for women/fetuses with particu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Outlines the five inclusion criteria (qualitative/mixed-methods study design, focus on routine ANC provision, population of skilled birth attendants per the 2004 WHO/ICM/FIGO definition as well as paid auxiliary and lay health workers in primary, secondary, or tertiary care, publication date range of January 2000 to August 2014, and no language restrictions) for the qualitative evidence synthesis of health-care providers' views and experiences (citing Downe et al., 2016).",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-122",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search terms",
      "pageStart": 125,
      "pageEnd": 125,
      "target": "../sections/sec-122-search-terms.md",
      "narrative": null,
      "content": "Participants\nArea of Interest\nContext\nPhenomenon of interest\nStudy design\nStaff or provider or health \ncare provider or nurs* \nor midwife* or physician \nor doctor or medical or \nfaculty or skilled birth \nattendant or auxiliary \nor lay or obstet* or \nworkforce or personnel \nAntenatal* or prenatal* or \nantepartum or perinatal \nor pregnan* \nCare or support or health \nor clinic or outpatient* or \noffice or education* or \nparentcraft or home or \nbirth centre or village or \ncommunit* or hospital or \ninstitution* or session or \nmaternal health services \nWant or like or desire \nor require or expect*",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the search term matrix (Participants, Area of Interest, Context, Phenomenon of interest, and Study design) and dual-reviewer screening, consensus adjudication, and back-/forward-chaining procedures for the qualitative meta-synthesis of health-care providers' views on routine antenatal care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-123",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Databases and other sources",
      "pageStart": 125,
      "pageEnd": 126,
      "target": "../sections/sec-123-databases-and-other-sources.md",
      "narrative": null,
      "content": "African Journals OnLine (AJOL), The Allied and Complementary Medicine Database (AMED), Cumulative Index to \nNursing and Allied Health Literature (CINAHL), Embase, Online Regional Information System for Scientific Journals \nfrom Latin America, the Caribbean, Spain and Portugal (Latindex), MEDLINE and PsycINFO. In addition, Zetoc alerts \nwere set up for over 50 relevant journals.\nWeb supplement: \nWHO recommendations on antenatal care for a positive pregnancy experience: evidence base\n118\nSearch strategies for the evidence base",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the electronic databases (AJOL, AMED, CINAHL, Embase, Latindex, MEDLINE, and PsycINFO) and Zetoc journal alerts (> 50 journals) searched for the qualitative meta-synthesis of health-care providers' views on antenatal care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-124",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search strategy for the review of factors affecting implementation of the WHO ANC guideline/recommendations (i.e. the 2016 WHO ANC model) – large-scale programme evaluation",
      "pageStart": 126,
      "pageEnd": 128,
      "target": "../sections/sec-124-4-search-strategy-for-the-review-of-factors-affe.md",
      "narrative": null,
      "content": "of the WHO ANC guideline/recommendations (i.e. the 2016 WHO \nANC model) – large-scale programme evaluation\nSearch strategy\ni. Electronic database searching and grey literature\nFor peer-reviewed literature, searches were conducted in the Cochrane Central Register of Controlled Trials \n(CENTRAL), MEDLINE, Embase, CINAHL Plus, Global Health and POPLINE, using a broad search strategy, with a \ndate restriction to include studies published after 2000 (when the WHO focused ANC Trial was registered) or 2002 \n(when the WHO ANC implementation guide was published)18. The search string for MEDLINE, which",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the three-part methodology for the large-scale programme evaluation review of factors affecting implementation of the WHO ANC guideline/FANC model: (i) electronic database searches (CENTRAL, MEDLINE, Embase, CINAHL Plus, Global Health, and POPLINE from 2000/2002 onwards using Cochrane ANC terms and the LMIC filter) plus grey literature from ministries of health and partner organizations; (ii) purposively sampled key informant interviews (up to five stakeholders per country case) analysed thematically using the SURE checklist; and (iii) compilation of country case profiles covering demographic, economic, maternal/neonatal health, resource, and ANC coverage indicators from WHO and World Bank datasets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-125",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search strategy for indirect evidence for health systems interventions",
      "pageStart": 128,
      "pageEnd": 128,
      "target": "../sections/sec-125-5-search-strategy-for-indirect-evidence-for-heal.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-126",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 128,
      "pageEnd": 128,
      "target": "../sections/sec-126-background.md",
      "narrative": null,
      "content": "The technical team considered the evidence base for the priority questions on health systems interventions and \nmade the judgement that indirect evidence of effects, to add to the existing direct evidence, should be searched for \nthree of the questions being considered: \n1.\t Should group ANC be recommended as an alternative to standard ANC?\n2.\t What kind of interventions should be recommended to communicate with, and support, pregnant women, their \npartners and communities about keeping healthy in pregnancy and using ANC services?\n3.\t Should pregnant women carry their own ANC case notes?\nThese",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the rationale, inclusion criteria (systematic reviews published since 2011 with relevant interventions and scoping outcomes), and exclusion criteria (major methodological limitations, low or very low certainty before downgrading for indirectness, or provider-targeted communication interventions) for searching indirect evidence on three health systems priority questions: group ANC, communication and support interventions for pregnant women and communities, and woman-held ANC case notes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    },
    {
      "id": "library/9789241549912-websupplement-eng/blocks/prose-sec-127",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods",
      "pageStart": 128,
      "pageEnd": 129,
      "target": "../sections/sec-127-methods.md",
      "narrative": null,
      "content": "Members of the technical team discussed how to maximize the possibility of finding relevant indirect evidence in the \ntime available. The following was agreed upon:\nFor questions 1 and 3 above, PDQ (“pretty darn quick”) Evidence21 was initially searched for relevant reviews \nfor group ANC (searching for “group care” for question 1, and “patient-held notes” for question 3). It was then \ndetermined to search terms by looking at the PubMed index terms and the MeSH terms of the reviews of direct \nevidence (Catling et al., 2015, and Ruiz-Merazo et al., 2012, for question 1; and Brown et al., 2015,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the rapid search methods used to identify indirect systematic review evidence in PDQ ('pretty darn quick') Evidence (using MeSH and PubMed index terms from direct reviews for group ANC and patient-held notes) and the Cochrane Consumers and Communication Review Group register (for communication and support interventions), followed by the back-matter ISBN (978 92 4 154991 2) and contact details for the WHO Departments of Reproductive Health and Research, Maternal, Newborn, Child and Adolescent Health, and Nutrition for Health and Development.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-10-30"
      }
    }
  ]
}
